[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 4103
1. Parashette KR, Makam RC, Cuffari C: Infliximab therapy in pediatric Crohn's disease: a review. Clin Exp Gastroenterol; 2010;3:57-63

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Although the ACCENT studies showed proven efficacy in the induction and maintenance of disease remission in adult patients with moderate to severe CD, the pediatric experience was instrumental in bringing forth the notion of "top-down" therapy to improve overall clinical response while reducing the risk of complications resulting from long-standing active disease.
  • Infliximab has proven efficacy in the induction and maintenance of disease remission in children and adolescents with CD.
  • In an open-labeled study of 112 pediatric patients with moderate to severe CD, 58% achieved clinical remission on induction of infliximab (5 mg/kg) therapy.
  • Among those patients who achieved disease remission, 56% maintained disease remission on maintenance (5 mg/kg every 8 weeks) therapy.
  • Moreover, these children have also been shown to improve overall growth while maintaining an effective disease remission.
  • The pediatric experience has been instructive in suggesting that the early introduction of anti-TNF-α therapy may perhaps alter the natural history of CD in children, an observation that has stimulated a great deal of interest among gastroenterologists who care for adult patients with CD.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gastroenterology. 1999 Oct;117(4):761-9 [10500056.001]
  • [Cites] N Engl J Med. 1998 Aug 6;339(6):370-4 [9691103.001]
  • [Cites] N Engl J Med. 2000 Jun 1;342(22):1627-32 [10833208.001]
  • [Cites] J Pediatr. 2000 Aug;137(2):192-6 [10931411.001]
  • [Cites] Gastroenterology. 2000 Oct;119(4):895-902 [11040176.001]
  • [Cites] Am J Gastroenterol. 2000 Nov;95(11):3189-94 [11095340.001]
  • [Cites] Aliment Pharmacol Ther. 2001 Apr;15(4):463-73 [11284774.001]
  • [Cites] N Engl J Med. 2001 Oct 11;345(15):1098-104 [11596589.001]
  • [Cites] Gastroenterology. 2001 Nov;121(5):1145-57 [11677207.001]
  • [Cites] Gut. 2002 Feb;50(2):206-11 [11788561.001]
  • [Cites] N Engl J Med. 2002 Feb 21;346(8):623-6 [11859881.001]
  • [Cites] J Pediatr Gastroenterol Nutr. 2002 Apr;34(4):410-2 [11930099.001]
  • [Cites] Lancet. 2002 May 4;359(9317):1541-9 [12047962.001]
  • [Cites] Aliment Pharmacol Ther. 2003 Jan;17(1):75-84 [12492735.001]
  • [Cites] Dis Colon Rectum. 1997 Oct;40(10 Suppl):S48-53 [9378012.001]
  • [Cites] J Pediatr Gastroenterol Nutr. 2003 Feb;36(2):248-52 [12548062.001]
  • [Cites] J Pediatr. 2003 Oct;143(4):525-31 [14571234.001]
  • [Cites] J Pediatr Gastroenterol Nutr. 2004 May;38(5):502-8 [15097438.001]
  • [Cites] Dig Liver Dis. 2004 May;36(5):342-7 [15191204.001]
  • [Cites] Inflamm Bowel Dis. 2004 Nov;10(6):745-50 [15626892.001]
  • [Cites] J Pediatr Gastroenterol Nutr. 2005 Feb;40(2):220-2 [15699701.001]
  • [Cites] Minerva Pediatr. 2006 Apr;58(2):139-57 [16835574.001]
  • [Cites] J Pediatr Gastroenterol Nutr. 2007 Feb;44(2):265-7 [17255842.001]
  • [Cites] Cytokine. 1995 Apr;7(3):251-9 [7640345.001]
  • [Cites] Gastroenterology. 1995 Apr;108(4):1056-67 [7698572.001]
  • [Cites] Gut. 1994 Mar;35(3):360-2 [8150347.001]
  • [Cites] Gut. 1993 Jun;34(6):778-82 [8314510.001]
  • [Cites] Gut. 1993 Jul;34(7):939-43 [8344582.001]
  • [Cites] J Clin Pathol. 1993 Aug;46(8):757-60 [8408704.001]
  • [Cites] Gut. 1997 Aug;41(2):209-14 [9301500.001]
  • [Cites] Aliment Pharmacol Ther. 1997 Oct;11(5):845-52 [9354191.001]
  • [Cites] N Engl J Med. 2003 Feb 13;348(7):601-8 [12584368.001]
  • [Cites] J Pediatr Gastroenterol Nutr. 2003 May;36(5):632-6 [12717087.001]
  • [Cites] Am J Gastroenterol. 2003 Apr;98(4):833-8 [12738464.001]
  • [Cites] Gastroenterology. 2003 Jul;125(1):32-9 [12851868.001]
  • [Cites] Aliment Pharmacol Ther. 2003 Aug 15;18(4):425-31 [12940928.001]
  • [Cites] Gut. 2003 Oct;52(10):1432-4 [12970135.001]
  • [Cites] Gastroenterology. 2004 Jan;126(1):19-31 [14699483.001]
  • [Cites] Gut. 2004 Sep;53(9):1363-5 [15306601.001]
  • [Cites] J Pediatr Gastroenterol Nutr. 2004 Sep;39(3):265-9 [15319627.001]
  • [Cites] Inflamm Bowel Dis. 2005 May;11(5):442-6 [15867583.001]
  • [Cites] Gut. 2006 Feb;55(2):228-33 [16120759.001]
  • [Cites] Clin Immunol. 2006 Jan;118(1):11-9 [16125467.001]
  • [Cites] Clin Gastroenterol Hepatol. 2006 May;4(5):621-30 [16678077.001]
  • [Cites] Gastroenterology. 2007 Jan;132(1):52-65 [17241859.001]
  • [Cites] Gastroenterology. 2007 Mar;132(3):863-73; quiz 1165-6 [17324398.001]
  • [Cites] J Pediatr Gastroenterol Nutr. 2007 Jul;45(1):3-14 [17592358.001]
  • [Cites] Drugs. 2007;67(12):1703-23 [17683171.001]
  • [Cites] Inflamm Bowel Dis. 2009 Mar;15(3):388-94 [19023899.001]
  • [Cites] Inflamm Bowel Dis. 2009 Jun;15(6):816-22 [19107783.001]
  • [Cites] J Pediatr Gastroenterol Nutr. 2009 Aug;49(2):183-90 [19561542.001]
  • [Cites] N Engl J Med. 1995 Feb 2;332(5):292-7 [7816064.001]
  • [Cites] N Engl J Med. 1994 Sep 29;331(13):836-41 [8078529.001]
  • [Cites] N Engl J Med. 1994 Sep 29;331(13):842-5 [8078530.001]
  • [Cites] Clin Exp Immunol. 1993 Oct;94(1):174-81 [8403503.001]
  • [Cites] Gut. 1995 Nov;37(5):674-8 [8549944.001]
  • [Cites] Aliment Pharmacol Ther. 2000 May;14(5):501-14 [10792111.001]
  • (PMID = 21694847.001).
  • [ISSN] 1178-7023
  • [Journal-full-title] Clinical and experimental gastroenterology
  • [ISO-abbreviation] Clin Exp Gastroenterol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] New Zealand
  • [Other-IDs] NLM/ PMC3108658
  • [Keywords] NOTNLM ; Crohn’s disease / infliximab / pediatric
  •  go-up   go-down


2. Berg AT, Vickrey BG, Langfitt JT, Sperling MR, Shinnar S, Bazil C, Walczak T, Spencer SS, Multicenter Study of Epilepsy Surgery: Reduction of AEDs in postsurgical patients who attain remission. Epilepsia; 2006 Jan;47(1):64-71
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Reduction of AEDs in postsurgical patients who attain remission.
  • PURPOSE: Little evidence guides practice regarding the reduction of antiepileptic drugs (AEDs) in individuals who achieve significant periods of remission after resective surgery.
  • RESULTS: Of 301 study subjects who attained a 1-year seizure remission after surgery, 129 reduced from two to one or from one to no AEDs after achieving remission, and 162 did not reduce drugs.
  • Ten patients who stopped all AEDs before attaining remission were excluded from analysis.
  • Within the 129 patients who reduced AEDs, only delayed remission after hospital discharge was significantly associated with an increased rate of relapse (RR, 2.26; 95% CI, 1.15- 4.48; p=0.02).
  • Continued auras had a marginally significant association with relapse (RR, 2.06; p=0.07) CONCLUSIONS: Although many relapses in this cohort of postsurgical patients who achieved remission occurred in the context of reducing or completely eliminating AEDs, the risk was no higher than in those who continued AEDs.
  • [MeSH-minor] Adult. Cohort Studies. Drug Administration Schedule. Follow-Up Studies. Hospitalization. Humans. Middle Aged. Patient Discharge. Postoperative Period. Prospective Studies. Risk Factors. Secondary Prevention. Survival Analysis. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16417533.001).
  • [ISSN] 0013-9580
  • [Journal-full-title] Epilepsia
  • [ISO-abbreviation] Epilepsia
  • [Language] eng
  • [Grant] United States / NINDS NIH HHS / NS / R01 NS 32375
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anticonvulsants
  •  go-up   go-down


3. de la Serna J, Montesinos P, Vellenga E, Rayón C, Parody R, León A, Esteve J, Bergua JM, Milone G, Debén G, Rivas C, González M, Tormo M, Díaz-Mediavilla J, González JD, Negri S, Amutio E, Brunet S, Lowenberg B, Sanz MA: Causes and prognostic factors of remission induction failure in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and idarubicin. Blood; 2008 Apr 1;111(7):3395-402
Hazardous Substances Data Bank. ALL-TRANS-RETINOIC ACID .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Causes and prognostic factors of remission induction failure in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and idarubicin.
  • An understanding of the prognostic factors associated with the various forms of induction mortality in patients with acute promyelocytic leukemia (APL) has remained remarkably limited.
  • Complete remission was attained in 666 patients (91%).
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / adverse effects. Hemorrhage / mortality. Infection / mortality. Leukemia, Promyelocytic, Acute / mortality
  • [MeSH-minor] Adolescent. Adult. Age Factors. Aged. Aged, 80 and over. Blast Crisis / blood. Blast Crisis / drug therapy. Blast Crisis / mortality. Child. Child, Preschool. Creatinine / blood. Disease-Free Survival. Female. Humans. Idarubicin / administration & dosage. Idarubicin / adverse effects. Male. Middle Aged. Remission Induction. Risk Factors. Sex Factors. Survival Rate. Syndrome. Treatment Failure. Tretinoin / administration & dosage. Tretinoin / adverse effects

  • Genetic Alliance. consumer health - Acute Promyelocytic Leukemia.
  • MedlinePlus Health Information. consumer health - Bleeding.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18195095.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 5688UTC01R / Tretinoin; AYI8EX34EU / Creatinine; ZRP63D75JW / Idarubicin
  •  go-up   go-down


Advertisement
4. Callaghan BC, Anand K, Hesdorffer D, Hauser WA, French JA: Likelihood of seizure remission in an adult population with refractory epilepsy. Ann Neurol; 2007 Oct;62(4):382-9
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Likelihood of seizure remission in an adult population with refractory epilepsy.
  • OBJECTIVE: We aimed to determine the likelihood of remission and its clinical predictors in adult patients meeting a strict definition of refractory epilepsy.
  • We also wanted to investigate the influence of treatment regimen on remission.
  • We used Kaplan-Meier methods to estimate the rate of achieving a 6-month terminal seizure remission and Cox regression analysis to evaluate clinical predictors for seizure remission.
  • RESULTS: The estimated 6-month terminal seizure remission rate was 19% (95% confidence interval, 14-26%) for all cases and 14% (95% confidence interval, 10-21%) when limited to those treated only with medication.
  • Negative predictors for remission included a history of status epilepticus, younger age at intractability, number of failed drug therapies, and presence of mental retardation.
  • No specific drug was significantly associated with remission, and frequently, no clear intervention led to terminal remission.
  • INTERPRETATION: Fifteen percent (approximately 5% per year) of a drug refractory epilepsy population obtained a 6-month terminal seizure remission.
  • Our results signify that no matter how many antiepileptic drug therapies have failed, there is always hope of a meaningful seizure remission in this population.
  • [MeSH-minor] Adult. Chronic Disease. Drug Administration Schedule. Drug Resistance. Drug Therapy, Combination. Female. Humans. Incidence. Male. Pennsylvania / epidemiology. Remission Induction. Retrospective Studies. Risk Factors. Treatment Outcome

  • Genetic Alliance. consumer health - Epilepsy.
  • MedlinePlus Health Information. consumer health - Epilepsy.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Ann Neurol. 2007 Oct;62(4):311-3 [17932974.001]
  • (PMID = 17880009.001).
  • [ISSN] 1531-8249
  • [Journal-full-title] Annals of neurology
  • [ISO-abbreviation] Ann. Neurol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anticonvulsants
  •  go-up   go-down


5. Kreft A, Holtmann H, Schad A, Kirkpatrick CJ: Detection of residual leukemic blasts in adult patients with acute T-lymphoblastic leukemia using bone marrow trephine biopsies: comparison of fluorescent immunohistochemistry with conventional cytologic and flow-cytometric analysis. Pathol Res Pract; 2010 Aug 15;206(8):560-4
Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Detection of residual leukemic blasts in adult patients with acute T-lymphoblastic leukemia using bone marrow trephine biopsies: comparison of fluorescent immunohistochemistry with conventional cytologic and flow-cytometric analysis.
  • Evaluation of remission in adult acute lymphoblastic leukemia (ALL) normally relies on cytologic evaluation and flow-cytometric analysis.
  • Regarding the evaluation of remission of T-ALL, in our retrospective study, bone marrow trephine biopsies with double immunostaining were found to be sensitive and specific for the detection of residual blasts.
  • [MeSH-major] Bone Marrow / pathology. Flow Cytometry. Fluorescent Antibody Technique. Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / diagnosis
  • [MeSH-minor] Adult. Biopsy. Cell Separation. Cytological Techniques. Female. Humans. Male. Middle Aged. Sensitivity and Specificity. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20413226.001).
  • [ISSN] 1618-0631
  • [Journal-full-title] Pathology, research and practice
  • [ISO-abbreviation] Pathol. Res. Pract.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


6. Wunderink L, Nienhuis FJ, Sytema S, Wiersma D: Predictive validity of proposed remission criteria in first-episode schizophrenic patients responding to antipsychotics. Schizophr Bull; 2007 May;33(3):792-6
MedlinePlus Health Information. consumer health - Schizophrenia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Predictive validity of proposed remission criteria in first-episode schizophrenic patients responding to antipsychotics.
  • The objective of this study was to examine the predictive validity of the remission criteria proposed by Andreasen et al in first-episode patients responding to antipsychotics.
  • Antipsychotic responsive patients with first-episode schizophrenia showing symptom remission (n = 60) were compared with patients who did not fulfill the proposed criteria (n = 65).
  • Patients in the remission group showed a significantly better outcome during follow-up on all Positive and Negative Syndrome Scale subscale scores (positive, negative, and general symptom subscales) and a significantly higher level of social functioning.
  • The proposed multidimensional criteria for symptomatic remission convey significant information when applied to first-episode patients who responded to antipsychotics, predicting outcome on the domains of both psychopathology and social functioning.
  • [MeSH-minor] Acute Disease. Adolescent. Adult. Female. Humans. Longitudinal Studies. Male. Middle Aged. Netherlands. Prognosis. Psychiatric Status Rating Scales / statistics & numerical data. Psychometrics. Quality of Life. Social Adjustment. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Acta Psychiatr Scand. 2006 Apr;113(4):332-9 [16638078.001]
  • [Cites] Acta Psychiatr Scand. 2006 Feb;113(2):91-5 [16423159.001]
  • [Cites] Qual Life Res. 2000 Feb;9(1):121-4 [10981212.001]
  • [Cites] Br J Psychiatry. 2001 Jun;178:506-17 [11388966.001]
  • [Cites] Schizophr Bull. 2002;28(2):203-22 [12693428.001]
  • [Cites] Am J Psychiatry. 2004 Mar;161(3):473-9 [14992973.001]
  • [Cites] Schizophr Bull. 1987;13(2):261-76 [3616518.001]
  • [Cites] Schizophr Bull. 1988;14(4):633-43 [3064287.001]
  • [Cites] Int J Rehabil Res. 1988;11(3):213-24 [2978514.001]
  • [Cites] Arch Gen Psychiatry. 1993 May;50(5):369-76 [8098203.001]
  • [Cites] Am J Psychiatry. 1994 Oct;151(10):1409-16 [8092334.001]
  • [Cites] Eur Child Adolesc Psychiatry. 1997 Dec;6(4):212-8 [9443000.001]
  • [Cites] J Nerv Ment Dis. 1998 Jun;186(6):357-63 [9653420.001]
  • [Cites] Am J Psychiatry. 2005 Mar;162(3):441-9 [15741458.001]
  • [Cites] Schizophr Bull. 2005 Jul;31(3):723-34 [16020553.001]
  • [Cites] Am J Psychiatry. 2000 May;157(5):808-15 [10784476.001]
  • (PMID = 16894026.001).
  • [ISSN] 0586-7614
  • [Journal-full-title] Schizophrenia bulletin
  • [ISO-abbreviation] Schizophr Bull
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antipsychotic Agents
  • [Other-IDs] NLM/ PMC2526146
  •  go-up   go-down


7. Chandesris MO, Ghez D, Besson C, Suarez F, Delarue R, Rubio MT, Bazarbachi A, Varet B, Hermine O: Complete remission of a relapsing adult T cell leukaemia following treatment of a secondary acute promyelocytic leukaemia: towards a reappraisal of arsenic trioxide and all-transretinoic acid? BMJ Case Rep; 2009;2009

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Complete remission of a relapsing adult T cell leukaemia following treatment of a secondary acute promyelocytic leukaemia: towards a reappraisal of arsenic trioxide and all-transretinoic acid?
  • Despite improvements in therapeutic options, human T cell lymphotropic virus type 1 (HTLV-1)-related adult T cell leukaemia/lymphoma (ATLL) has a dismal prognosis.
  • The present report concerns the case of a multirelapsing ATLL that reached a complete remission following the treatment of a secondary acute promyelocytic leukaemia with cytarabine, anthracyclin, all-transretinoic acid and arsenic trioxide.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Haematologica. 2007 May;92(5):719-20 [17488707.001]
  • [Cites] Antiviral Res. 2006 Jul;70(3):132-9 [16540180.001]
  • [Cites] Blood. 2000 Oct 15;96(8):2849-55 [11023521.001]
  • [Cites] Oncogene. 2005 Sep 5;24(39):6058-68 [16155612.001]
  • [Cites] Hematol J. 2002;3(6):276-82 [12522449.001]
  • [Cites] Blood. 2003 Jun 1;101(11):4576-82 [12560223.001]
  • [Cites] J Clin Oncol. 2003 Jun 15;21(12):2326-34 [12805334.001]
  • [Cites] J Infect Dis. 2003 Aug 1;188(3):424-7 [12870124.001]
  • [Cites] Haematologica. 2007 Jun;92(6):753-62 [17550847.001]
  • [Cites] Cell Death Differ. 2005 Aug;12 Suppl 1:871-7 [15846376.001]
  • [Cites] Leukemia. 2005 Jun;19(6):1010-7 [15843825.001]
  • [Cites] Hematol J. 2004;5(2):130-4 [15048063.001]
  • [Cites] Blood. 1999 Jan 1;93(1):278-83 [9864171.001]
  • [Cites] Leuk Lymphoma. 2005 Mar;46(3):347-55 [15621824.001]
  • [Cites] Lancet Oncol. 2004 Nov;5(11):664-72 [15522654.001]
  • (PMID = 21829417.001).
  • [ISSN] 1757-790X
  • [Journal-full-title] BMJ case reports
  • [ISO-abbreviation] BMJ Case Rep
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC3030139
  •  go-up   go-down


8. Yang H, Kadia T, Xiao L, Bueso-Ramos CE, Hoshino K, Thomas DA, O'Brien S, Jabbour E, Pierce S, Rosner GL, Kantarjian HM, Garcia-Manero G: Residual DNA methylation at remission is prognostic in adult Philadelphia chromosome-negative acute lymphocytic leukemia. Blood; 2009 Feb 26;113(9):1892-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Residual DNA methylation at remission is prognostic in adult Philadelphia chromosome-negative acute lymphocytic leukemia.
  • Pretreatment aberrant DNA methylation patterns are stable at time of relapse in acute lymphocytic leukemia (ALL).
  • We hypothesized that the detection of residual methylation alterations at the time of morphologic remission may predict for worse prognosis.
  • We developed a real-time bisulfite polymerase chain reaction assay and analyzed the methylation levels of p73, p15, and p57(KIP2) at the time of initial remission in 199 patients with Philadelphia chromosome-negative and MLL(-) ALL.
  • In 123 (65%) patients, matched pretreatment samples were also studied and compared with remission ones: in 82 of those with initial aberrant methylation of at least one gene, 59 (72%) had no detectable methylation at remission and 23 (28%) had detectable residual methylation.
  • By multivariate analysis, the presence of residual p73 methylation was associated with a significant shorter duration of first complete remission (hazard ratio=2.68, P= .003) and overall survival (hazard ratio=2.69, P= .002).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2000 Feb;18(3):547-61 [10653870.001]
  • [Cites] Nucleic Acids Res. 2008 Jan;36(Database issue):D25-30 [18073190.001]
  • [Cites] Hematol Oncol Clin North Am. 2001 Feb;15(1):163-205 [11253606.001]
  • [Cites] Nat Rev Genet. 2000 Oct;1(1):11-9 [11262868.001]
  • [Cites] Nat Rev Genet. 2002 Jun;3(6):415-28 [12042769.001]
  • [Cites] Clin Cancer Res. 2002 Jun;8(6):1897-903 [12060634.001]
  • [Cites] Clin Cancer Res. 2002 Jul;8(7):2217-24 [12114423.001]
  • [Cites] Blood. 2003 May 15;101(10):4131-6 [12586619.001]
  • [Cites] Leukemia. 2003 Sep;17(9):1845-50 [12970785.001]
  • [Cites] N Engl J Med. 2004 Apr 8;350(15):1535-48 [15071128.001]
  • [Cites] Blood. 2004 Jun 15;103(12):4396-407 [14551133.001]
  • [Cites] Blood. 2004 Oct 15;104(8):2492-8 [15198948.001]
  • [Cites] Hematol Oncol Clin North Am. 1993 Feb;7(1):139-60 [8449856.001]
  • [Cites] Nucleic Acids Res. 1997 Jun 15;25(12):2532-4 [9171110.001]
  • [Cites] J Clin Oncol. 2005 Jun 10;23(17):3932-9 [15851765.001]
  • [Cites] Leuk Res. 2005 Aug;29(8):881-5 [15978938.001]
  • [Cites] Blood. 2006 Nov 15;108(10):3271-9 [16882711.001]
  • [Cites] Cancer Res. 2007 Feb 1;67(3):1370-7 [17283175.001]
  • [Cites] Hematol Oncol Clin North Am. 2000 Dec;14(6):1381-96, x-xi [11147229.001]
  • (PMID = 19109226.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R21 CA105771; United States / NCI NIH HHS / CA / P30 CA016672; United States / NCI NIH HHS / CA / CA100067; United States / NCI NIH HHS / CA / R21 CA100067; United States / NCI NIH HHS / CA / CA105771
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cyclin-Dependent Kinase Inhibitor p15; 0 / Cyclin-Dependent Kinase Inhibitor p57; 0 / DNA-Binding Proteins; 0 / Nuclear Proteins; 0 / Tumor Suppressor Proteins; 0 / tumor suppressor protein p73
  • [Other-IDs] NLM/ PMC2651008
  •  go-up   go-down


9. Gong JF, Niu LY, Wei XW, Zhu WM, Li N, Li JS: [Therapeutic effects of combined enteral nutrition with Tripterygium Wilfordii poly-glycoside in remission induction of active adult Crohn's disease]. Zhonghua Wai Ke Za Zhi; 2009 Aug 15;47(16):1213-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Therapeutic effects of combined enteral nutrition with Tripterygium Wilfordii poly-glycoside in remission induction of active adult Crohn's disease].
  • OBJECTIVE: To investigate the potential role of enteral nutrition (EN) combined with Tripterygium Wilfordii Poly-glycoside (TWP) for remission induction of active adult Crohn's disease (CD).
  • METHODS: Clinical data of 62 adult patients with active CD treated with EN and TWP in combination (n = 42) or TWP alone (n = 20) from March 2001 to September 2008 were retrospectively analyzed.
  • Clinical response was defined by a decrease of at least 70 points in the CDAI from baseline after treatment, and clinical remission was defined as the absolute value of CDAI (less than 150).
  • RESULTS: The ratio of clinical response (78.6% vs. 40.0%, P = 0.003) and clinical remission (69.1% vs. 30.0%, P = 0.004) were both significantly higher in the combined treatment group than in those the TWP group at week 4.
  • At week 12, the clinical response ratio was significantly higher in the combined treatment group (90.5% vs. 65.0%, P = 0.014); the remission ratio was also higher in the combined treatment group (76.2% vs. 55.0%, P = 0.091).
  • CONCLUSIONS: Treatment with enteral nutrition and TWP in combination are superior to TWP alone for induction of clinical response and remission in adult Crohn's Disease.
  • [MeSH-minor] Adolescent. Adult. Aged. Combined Modality Therapy. Female. Follow-Up Studies. Humans. Male. Middle Aged. Remission Induction. Retrospective Studies. Treatment Outcome. Young Adult


10. Mao ZF, Mo XA, Qin C, Lai YR, Olde Hartman TC: Course and prognosis of myasthenia gravis: a systematic review. Eur J Neurol; 2010 Jul;17(7):913-21
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The clinical course of myasthenia gravis (MG) is variable, and spontaneous remission is still uncommon.
  • Studies evaluating variables associated with or predictive of remission in adult patients with MG were included.
  • The included studies were heterogeneous considerably in sample size, disease duration, follow-up years, definition of remission, and analysis.
  • Time of diagnosis from onset (<1 year) showed strong evidence of predicting a better remission.
  • In studies using completely stable remission outcomes, there was strong evidence that age at onset (<40 years) was of prognostic importance.
  • Furthermore, gender showed no association with remission.
  • Time of diagnosis from onset and age at onset were found to be predictors of remission.


11. de Ridder L, Benninga MA, Taminiau JA, Hommes DW, van Deventer SJ: Infliximab use in children and adolescents with inflammatory bowel disease. J Pediatr Gastroenterol Nutr; 2007 Jul;45(1):3-14
Hazardous Substances Data Bank. Infliximab .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Large randomized controlled trials have shown the efficacy and safety of infliximab for the induction and maintenance of remission in adult patients with active Crohn disease (CD).
  • An efficient remission induction strategy consists of 3 initial infliximab infusions at 0, 2, and 6 weeks in a dosage of 5 mg/kg to sustain remission.
  • [MeSH-minor] Adolescent. Adult. Child. Humans. Infliximab

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17592358.001).
  • [ISSN] 1536-4801
  • [Journal-full-title] Journal of pediatric gastroenterology and nutrition
  • [ISO-abbreviation] J. Pediatr. Gastroenterol. Nutr.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents; 0 / Antibodies, Monoclonal; 0 / Tumor Necrosis Factor-alpha; B72HH48FLU / Infliximab
  • [Number-of-references] 91
  •  go-up   go-down


12. Wolter A, Preuss U, Krischke N, Wong JW, Langosch JM, Zimmermann J: [Recovery and remission in schizophrenia. Results from a naturalistic 2-year follow-up inpatient study]. Fortschr Neurol Psychiatr; 2010 Aug;78(8):468-74
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Recovery and remission in schizophrenia. Results from a naturalistic 2-year follow-up inpatient study].
  • [Transliterated title] Recovery und Remission bei Schizophrenie. Ergebnisse einer naturalistischen 2-Jahres-Katamnesestudie ehemals stationärer Patienten.
  • INTRODUCTION: Remission in schizophrenia is defined as a period of at least 6 months in which symptom reduction occurs.
  • Criteria of remission for each domain were assessed using the BPRS (brief psychiatric rating scale, symptomatic remission), GAF (global assessment of functioning, functional remission) and the SWN-K (subjective well-being under neuroleptics, remission of subjective well-being).
  • Approximately one-third of the individuals had remission with a stable quality of life.
  • CONCLUSION: Compared to previous studies, the rates of remission and recovery in the current sample were quite low.
  • [MeSH-minor] Adult. Age of Onset. Antipsychotic Agents / therapeutic use. Female. Follow-Up Studies. Humans. Inpatients. Longitudinal Studies. Male. Middle Aged. Prospective Studies. Psychiatric Status Rating Scales. Quality of Life. Recovery of Function. Remission, Spontaneous

  • Genetic Alliance. consumer health - Schizophrenia.
  • MedlinePlus Health Information. consumer health - Schizophrenia.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) Georg Thieme Verlag KG Stuttgart--New York.
  • (PMID = 20694939.001).
  • [ISSN] 1439-3522
  • [Journal-full-title] Fortschritte der Neurologie-Psychiatrie
  • [ISO-abbreviation] Fortschr Neurol Psychiatr
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antipsychotic Agents
  •  go-up   go-down


13. Senthil Nayagam L, Ganguli A, Rathi M, Kohli HS, Gupta KL, Joshi K, Sakhuja V, Jha V: Mycophenolate mofetil or standard therapy for membranous nephropathy and focal segmental glomerulosclerosis: a pilot study. Nephrol Dial Transplant; 2008 Jun;23(6):1926-30
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: We compared the efficacy of an MMF-based therapy with standard therapies in inducing remission in adult nephrotics with MN and FSGS in a randomized pilot study.
  • There was no difference in the proportion of patients achieving remission in two groups (64 and 80% in MN and 70 and 69% in FSGS).
  • FSGS patients in group A achieved remission faster and received a lower cumulative steroid dose.
  • It induces remission faster and reduces steroid exposure in FSGS patients.
  • [MeSH-minor] Adolescent. Adult. Anti-Inflammatory Agents, Non-Steroidal / therapeutic use. Dose-Response Relationship, Drug. Drug Administration Schedule. Drug Therapy, Combination. Female. Follow-Up Studies. Humans. Kidney Function Tests. Male. Pilot Projects. Probability. Risk Assessment. Severity of Illness Index. Statistics, Nonparametric. Treatment Outcome

  • Genetic Alliance. consumer health - Focal Segmental Glomerulosclerosis.
  • Genetic Alliance. consumer health - Membranous nephropathy.
  • Hazardous Substances Data Bank. MYCOPHENOLATE MOFETIL .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Nephrol Dial Transplant. 2008 Jun;23(6):1793-6 [18441003.001]
  • (PMID = 17989103.001).
  • [ISSN] 1460-2385
  • [Journal-full-title] Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association
  • [ISO-abbreviation] Nephrol. Dial. Transplant.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents, Non-Steroidal; 8N3DW7272P / Cyclophosphamide; 9242ECW6R0 / mycophenolate mofetil; 9PHQ9Y1OLM / Prednisolone; HU9DX48N0T / Mycophenolic Acid
  •  go-up   go-down


14. Iwamoto M, Wakabayashi M, Hanada S, Kobayashi N, Hata T, Ando R: [Case of Henoch-Schönlein purpura nephritis successfully treated with tonsillectomy and steroid pulse therapy]. Nihon Jinzo Gakkai Shi; 2009;51(4):484-9
Hazardous Substances Data Bank. METHYLPREDNISOLONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The patient finally achieved clinical remission.
  • Recent reports have shown that in patients with IgA nephropathy, combined tonsillectomy and methylprednisolone pulse therapy have an effect on clinical remission.
  • The result of this case indicated that this combination therapy had a favorable effect on clinical remission in adult patients with HSPN.
  • [MeSH-minor] Adult. Combined Modality Therapy. Drug Therapy, Combination. Humans. Male. Prednisolone / administration & dosage. Pulse Therapy, Drug. Treatment Outcome

  • Genetic Alliance. consumer health - Henoch-Schonlein purpura.
  • MedlinePlus Health Information. consumer health - Tonsillitis.
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19601558.001).
  • [ISSN] 0385-2385
  • [Journal-full-title] Nihon Jinzo Gakkai shi
  • [ISO-abbreviation] Nihon Jinzo Gakkai Shi
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 9PHQ9Y1OLM / Prednisolone; X4W7ZR7023 / Methylprednisolone
  •  go-up   go-down


15. Degmecić D, Pozgain I, Filaković P, Dodig-Curković K, Mihanović M: Psychopharmacotherapy and remission of patients with schizophrenia. Coll Antropol; 2009 Jun;33(2):547-51
MedlinePlus Health Information. consumer health - Schizophrenia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Psychopharmacotherapy and remission of patients with schizophrenia.
  • Schizophrenia is a clinical syndrome of variable, but profoundly disruptive, psychopathology that involves cognition, emotion, perception and other aspects of behavior The Remission in Schizophrenia Working Group (RSWG) has defined criteria for symptomatic remission based on achieving and maintaining a consistently low symptom threshold for at least six consecutive months.
  • Aim of our study was to determine which antipsychotic are used in the treatment of patients with schizophrenia, as well as to assess are there differences between patients treated with typical and atypical antipsychotics and how many of them are in remission according to the defined remission criteria.
  • All of them were assessed with specially designed questionnaire about sociodemographic data, than with 8 item of PANSS (remission criteria), and with Clinical Global Impression scale.
  • Authors did not found statistically significant differences in two groups of patients regarding the scores on PANSS, CGI and number of patients in remission.
  • [MeSH-minor] Adult. Female. Humans. Male. Middle Aged. Psychopharmacology. Remission Induction. Surveys and Questionnaires

  • Genetic Alliance. consumer health - Schizophrenia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19662777.001).
  • [ISSN] 0350-6134
  • [Journal-full-title] Collegium antropologicum
  • [ISO-abbreviation] Coll Antropol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Croatia
  • [Chemical-registry-number] 0 / Antipsychotic Agents
  •  go-up   go-down


16. Faderl S, Thomas DA, Gandhi V, Huang X, Borthakur G, O'Brien S, Ravandi F, Plunkett W, Bretz JL, Kantarjian HM: Results of a phase I study of clofarabine (CLO) plus cyclophosphamide (CY) in adult patients (pts) with relapsed and/or refractory acute lymphoblastic leukemia (ALL). J Clin Oncol; 2009 May 20;27(15_suppl):7020

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Results of a phase I study of clofarabine (CLO) plus cyclophosphamide (CY) in adult patients (pts) with relapsed and/or refractory acute lymphoblastic leukemia (ALL).
  • Single agent CLO in adult ALL was less active so that combinations of CLO with other active agents are pursued.
  • Twenty-one pts had pre-B ALL, 5 pts pre-T/T ALL, 1 pt mature B ALL, and 3 pts biphenotypic acute leukemias.
  • Among the remainder, preceding median remission duration was 8.6 mos (1-39 mos).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961382.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


17. Ferron G, Aziza R, Delannes M, Filleron T, Marquès B, Labarre D, Labarre D, Chevreau C: Detection of local recurrences of limb soft-tissue sarcomas: Is magnetic resonance imaging (MRI) relevant? J Clin Oncol; 2009 May 20;27(15_suppl):10582

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The aim of our study was to retrospectively evaluate the effectiveness of a MRI surveillance schedule performed in adult patients.
  • METHODS: 124 adult patients have been treated from 1996 to 2006 for a non-metastatic limb STS at our centre: 86 patients (70%) had clear resection margins (R0) and 111 patients (90%) received an adjuvant radiotherapy.
  • RESULTS: Forty-one patients (33%) prematurely withdrew from the planned radiological surveillance due to metastasis diagnosis (15 cases), 5-year remission duration (5 cases), other reasons (12 cases), and drop out (9 cases).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963876.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


18. Erba HP, Kantarjian HM, Claxton DF, Arellano M, Lyons RM, Kovacsovics TJ, Gabrilove J, Eckert S, Faderl S: Updated remission duration and survival results of single-agent clofarabine in previously untreated older adult patients with acute myelogenous leukemia (AML) unlikely to benefit from standard induction chemotherapy due to unfavorable baseline risk factor(s). J Clin Oncol; 2009 May 20;27(15_suppl):7062

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Updated remission duration and survival results of single-agent clofarabine in previously untreated older adult patients with acute myelogenous leukemia (AML) unlikely to benefit from standard induction chemotherapy due to unfavorable baseline risk factor(s).
  • : 7062 Background: The CLASSIC II trial has previously reported an independently confirmed overall remission rate of 46% (38% CR and 8% CRp) and 30- and 60-day mortality rates of 9.8% and 16.1%, respectively (Blood 112: 558, 2008).
  • We now report updated duration of remission (DOR), disease-free survival (DFS), and overall survival (OS).
  • Patients were followed for at least 6 months past remission (CR/CRp).
  • CONCLUSIONS: These data expand on the previously reported efficacy and safety data of single agent CLO in adult AML.
  • These results suggest that single agent CLO is an effective and tolerable treatment option for older adult patients with untreated AML and 1 or more unfavorable baseline prognostic factor(s).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961436.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


19. Lonetti A, Iacobucci I, Ferrari A, Messina M, Cilloni D, Soverini S, Papayannidis C, Baccarani M, Foà R, Martinelli G: Expression of different isoforms of the B-cell mutator activation-induced cytidine deaminase (AID) in BCR-ABL1-positive acute lymphoblastic leukemia (ALL) patients. J Clin Oncol; 2009 May 20;27(15_suppl):7049

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of different isoforms of the B-cell mutator activation-induced cytidine deaminase (AID) in BCR-ABL1-positive acute lymphoblastic leukemia (ALL) patients.
  • : 7049 Since the activation-induced cytidine deaminase (AID) enzyme can target non-immunoglobulin (Ig) genes and may even act as a genome-wide mutator, we investigated AID expression in BCR-ABL1-positive ALL and in chronic myeloid leukemia (CML) at the time of progression to blast crisis.
  • On the 61 de novo adult BCR-ABL1-positive ALL patients (pts), AID mRNA and protein were detected in 36 (59%); their expression correlated with BCR-ABL1 transcript levels and disappeared after treatment with tyrosine kinase inhibitors at the time of remission.
  • AID expression was also found in lymphoid blast crisis CML (50%), but not in myeloid lineage or in chronic phase CML.
  • Our findings show that BCR-ABL1-positive ALL cells aberrantly express different isoforms of AID that can act as mutator outside the Ig gene loci in promoting genetic instability in leukemia cells.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961429.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


20. Bonini A, Tieghi A, Gamberi B, Imovilli A, Carbonelli C, Spaggiari L, Gugliotta L: Caspofungin for invasive aspergillosis: A single-centre prospective study. J Clin Oncol; 2009 May 20;27(15_suppl):e20618

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Since 2004 we began a prospective study with the administration of Caspo as first line therapy in 63 consecutive adult neutropenic pts.
  • The diagnoses were: leukemia 44, myeloma 3, lymphoma 16; the disease's phases were: new onset 24, remission 16, relapse 23.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961616.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


21. Hafeez M, Shaharyar A, Zia N, Rasheed H: A phase II feasibility study of cytarabine and idarubicin combination in relapsed or refractory adult acute lymphoblastic leukemia. J Clin Oncol; 2009 May 20;27(15_suppl):e18002

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase II feasibility study of cytarabine and idarubicin combination in relapsed or refractory adult acute lymphoblastic leukemia.
  • : e18002 Background: Most patients with adult ALL eventually relapse.
  • It was empirically decided that the study will only be considered feasible if more then ten patients achieve a complete remission.
  • Eleven patients achieved complete remission.
  • CONCLUSIONS: The regimen of cytrarabine and idarubicin is feasible and sufficiently effective in relapsed or refractory adult ALL with manageable toxicity.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964000.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


22. Pemmaraju N, Kantarjian H, Ravandi F, O'Brien S, Wierda W, Thomas D, Garcia-Manero G, Borthakur G, Pierce S, Cortes J: Acute myeloid leukemia (AML) in adolescents and young adults (AYA): The M. D. Anderson Cancer Center (MDACC) experience. J Clin Oncol; 2009 May 20;27(15_suppl):7051

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acute myeloid leukemia (AML) in adolescents and young adults (AYA): The M. D. Anderson Cancer Center (MDACC) experience.
  • RESULTS: Among 3,934 adult AML pts treated during this period, 163 pts (4%) were AYA with median age of 19 yrs.
  • This cohort included 27 (17%) pts with Core Binding Factor (CBF)-AML [inv(16), t(8:21)] and 19 pts (12%) with acute promyelocytic leukemia (APL).
  • Complete remission (CR) rates were 89% for CBF AML, 79% for APL, and 75% for all other pts.
  • Outcome is better for pts with CBF leukemia (3 yr survival 56%, sustained CR 49%) and APL (3 yr survival 51%, sustained CR 36%) compared to other AML (3 yr survival 28%, sustained CR 24%).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961415.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


23. Cervantes-Castaneda RA, Bhat P, Fortuna E, Acevedo S, Foster CS: Induction of durable remission in ocular inflammatory diseases. Eur J Ophthalmol; 2009 Jan-Feb;19(1):118-23
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Induction of durable remission in ocular inflammatory diseases.
  • PURPOSE: To describe a paradigm of care for patients with ocular inflammatory diseases aimed at induction of durable remission.
  • Durable remission was defined as control of inflammation in the absence of systemic IMT for at least 1 year.
  • Thirty percent of the patients required at least 2 years of therapy with systemic IMT to obtain durable remission, while 44% required 2 to 5 years of therapy to achieve the same.
  • Twenty percent continued to stay in remission, off immunomodulatory drugs, between 2 and 5 years and 18% were in remission for more than 5 years after therapy discontinuation.
  • Durable drug-free remission is an achievable goal, and should be pursued by ocular inflammatory disease specialists.
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Female. Humans. Immunosuppressive Agents / therapeutic use. Inflammation / drug therapy. Male. Middle Aged. Retrospective Studies. Treatment Failure. Young Adult

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19123158.001).
  • [ISSN] 1120-6721
  • [Journal-full-title] European journal of ophthalmology
  • [ISO-abbreviation] Eur J Ophthalmol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Immunologic Factors; 0 / Immunosuppressive Agents
  •  go-up   go-down


24. Hallböök H, Hägglund H, Stockelberg D, Nilsson PG, Karlsson K, Björkholm M, Linderholm M, Wahlin A, Linder O, Smedmyr B, Swedish Adult ALL Group: Autologous and allogeneic stem cell transplantation in adult ALL: the Swedish Adult ALL Group experience. Bone Marrow Transplant; 2005 Jun;35(12):1141-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Autologous and allogeneic stem cell transplantation in adult ALL: the Swedish Adult ALL Group experience.
  • Adult patients with acute lymphoblastic leukaemia (ALL) have been treated according to national protocols in Sweden since 1986.
  • Stem cell transplantation (SCT) has been recommended in first remission for patients with risk factors for relapse, and for standard risk patients only after relapse.
  • The 5-year DFS was higher for patients transplanted in first remission 32% (CI 24-40%) compared to 14% (CI 5-23%; P<0.0001) in patients transplanted beyond first remission.
  • [MeSH-major] Hematopoietic Stem Cell Transplantation / methods. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Disease-Free Survival. Female. Graft vs Host Disease. Graft vs Leukemia Effect. Humans. Male. Middle Aged. Philadelphia Chromosome. Probability. Recurrence. Retrospective Studies. Sweden. Tissue Donors. Transplantation, Autologous. Transplantation, Homologous

  • Genetic Alliance. consumer health - Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15834433.001).
  • [ISSN] 0268-3369
  • [Journal-full-title] Bone marrow transplantation
  • [ISO-abbreviation] Bone Marrow Transplant.
  • [Language] eng
  • [Publication-type] Comparative Study; Evaluation Studies; Journal Article
  • [Publication-country] England
  •  go-up   go-down


25. Schimmele CM, Wu Z, Penning MJ: Gender and remission of mental illness. Can J Public Health; 2009 Sep-Oct;100(5):353-6
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gender and remission of mental illness.
  • The objective of this study was to determine whether gender also influences the timing of remission from illness.
  • The regression analysis undertaken considered remission in terms of all ICD-9 mental disorders (codes 290-314).
  • This analysis compares males and females on average length of treatment for mental illness and examines whether any gender differences in remission are generalized or disorder specific.
  • RESULTS: There was a non-significant bivariate relation between gender and the timing of remission from mental illness.
  • However, the multivariate findings demonstrated that a significant gender effect on remission emerges after controls were introduced for demographic and socio-economic characteristics.
  • In particular, the timing of remission was somewhat longer for females.
  • CONCLUSIONS: The emergence of a significant effect after considering demographic and socio-economic characteristics suggests that a social disadvantage within the male sample (more single males) was suppressing a small negative effect of female gender on the timing of remission.
  • In other words, a social disadvantage among males concealed an unexplained female disadvantage in remission.

  • Genetic Alliance. consumer health - Mental Illness.
  • MedlinePlus Health Information. consumer health - Mental Disorders.
  • MedlinePlus Health Information. consumer health - Mental Health.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19994736.001).
  • [ISSN] 0008-4263
  • [Journal-full-title] Canadian journal of public health = Revue canadienne de sante publique
  • [ISO-abbreviation] Can J Public Health
  • [Language] ENG
  • [Grant] United States / NICHD NIH HHS / HD / R24 HD042828; None / None / / R24 HD042828-10; United States / NICHD NIH HHS / HD / R24 HD042828-10; Canada / Canadian Institutes of Health Research / /
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Canada
  •  go-up   go-down


26. Trivedi MH, Corey-Lisle PK, Guo Z, Lennox RD, Pikalov A, Kim E: Remission, response without remission, and nonresponse in major depressive disorder: impact on functioning. Int Clin Psychopharmacol; 2009 May;24(3):133-8
MedlinePlus Health Information. consumer health - Antidepressants.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Remission, response without remission, and nonresponse in major depressive disorder: impact on functioning.
  • At the end of double-blind treatment, patients were defined as: in remission [>or=50% reduction in Montgomery-Asberg Depression Rating Scale (MADRS) score with MADRS <or=10]; with a response without remission (>or=50% reduction in MADRS with MADRS >10); or with a nonresponse (all others).
  • Of the 679 patients, 144 were in remission, 44 had a response without remission, and 491 had a nonresponse.
  • Mean improvements in the Sheehan Disability Scale total and item scores were significantly greater in patients in remission versus those with a response without remission (P<0.02) as well as nonresponse (P<0.001).
  • In conclusion, MDD patients achieving symptomatic remission experience greater functional improvements than those respond without remission.
  • Treatments focused on producing high remission rates may improve patient functioning over and above that seen with patients who only achieve response.
  • [MeSH-minor] Adult. Algorithms. Aripiprazole. Data Interpretation, Statistical. Disability Evaluation. Double-Blind Method. Drug Therapy, Combination. Female. Humans. Male. Middle Aged. Models, Statistical. Psychiatric Status Rating Scales. Randomized Controlled Trials as Topic. Socioeconomic Factors. Treatment Failure

  • Genetic Alliance. consumer health - Major depressive disorder.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19318972.001).
  • [ISSN] 1473-5857
  • [Journal-full-title] International clinical psychopharmacology
  • [ISO-abbreviation] Int Clin Psychopharmacol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antidepressive Agents; 0 / Antipsychotic Agents; 0 / Piperazines; 0 / Quinolones; 82VFR53I78 / Aripiprazole
  •  go-up   go-down


27. Orsi C, Bartolozzi B, Messori A, Bosi A: Event-free survival and cost-effectiveness in adult acute lymphoblastic leukaemia in first remission treated with allogeneic transplantation. Bone Marrow Transplant; 2007 Oct;40(7):643-9
MedlinePlus Health Information. consumer health - Bone Marrow Transplantation.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Event-free survival and cost-effectiveness in adult acute lymphoblastic leukaemia in first remission treated with allogeneic transplantation.
  • Allogeneic transplantation in patients with acute lymphoblastic leukaemia in first remission (ALL-CR1) has been studied in several clinical trials.
  • [MeSH-major] Bone Marrow Transplantation / physiology. Disease-Free Survival. Precursor Cell Lymphoblastic Leukemia-Lymphoma / surgery. Transplantation, Homologous

  • Genetic Alliance. consumer health - Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17660839.001).
  • [ISSN] 0268-3369
  • [Journal-full-title] Bone marrow transplantation
  • [ISO-abbreviation] Bone Marrow Transplant.
  • [Language] eng
  • [Publication-type] Controlled Clinical Trial; Journal Article
  • [Publication-country] England
  •  go-up   go-down


28. Moos RH, Moos BS: Paths of entry into alcoholics anonymous: consequences for participation and remission. Alcohol Clin Exp Res; 2005 Oct;29(10):1858-68
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Paths of entry into alcoholics anonymous: consequences for participation and remission.
  • They also described their reasons for entering AA and/or treatment and the perceived benefits of these sources of help RESULTS: Compared with individuals who initially participated only in treatment but later entered AA, those who entered treatment and AA together participated in AA longer and more frequently and were more likely to achieve remission.
  • Among individuals who initially participated only in AA, those who later entered treatment had poorer remission outcomes than those who did not enter treatment.
  • Longer duration of participation in AA was associated with a higher likelihood of remission at all four follow-ups; individuals who dropped out of AA were more likely to relapse or remain nonremitted.
  • CONCLUSIONS: Compared with individuals who participated only in professional treatment in the first year after they initiated help-seeking, individuals who participated in both treatment and AA were more likely to achieve remission.
  • [MeSH-minor] Adult. Alcohol Drinking / psychology. Female. Humans. Life Style. Logistic Models. Male. Motivation. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Alcoholism and Alcohol Abuse.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16269916.001).
  • [ISSN] 0145-6008
  • [Journal-full-title] Alcoholism, clinical and experimental research
  • [ISO-abbreviation] Alcohol. Clin. Exp. Res.
  • [Language] eng
  • [Grant] United States / NIAAA NIH HHS / AA / AA12718
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  •  go-up   go-down


29. Yoshimura R, Umene-Nakano W, Ueda N, Ikenouchi-Sugita A, Hori H, Katsuki A, Hayashi K, Miyamoto K, Kodama Y, Nakamura J: No difference in adherence to paroxetine between depressed patients with early remission and those with late remission based on monitoring of plasma paroxetine concentrations. Hum Psychopharmacol; 2010 Aug;25(6):487-90
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] No difference in adherence to paroxetine between depressed patients with early remission and those with late remission based on monitoring of plasma paroxetine concentrations.
  • Twelve patients (M/F: 7/13, age: 37.4 +/- 10.4 years) were treated with paroxetine (40 mg/day), and all achieved remission (HAMD < or = 7) within at least 12 weeks.
  • We divided the patients into two groups, an early-remission group (HAMD < or = 7 within 4 weeks) and a late-remission group (HAMD < or = 7 within 8-12 weeks).
  • The paroxetine concentrations in the early-remission group were significantly decreased 12 weeks after discharge, and no difference was found between the early- and late-remission groups.
  • [MeSH-minor] Adult. Dose-Response Relationship, Drug. Female. Hospitals, University. Humans. Inpatients. Male. Treatment Outcome

  • Hazardous Substances Data Bank. PAROXETINE HYDROCHLORIDE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 John Wiley & Sons, Ltd.
  • (PMID = 20725911.001).
  • [ISSN] 1099-1077
  • [Journal-full-title] Human psychopharmacology
  • [ISO-abbreviation] Hum Psychopharmacol
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Serotonin Uptake Inhibitors; 41VRH5220H / Paroxetine
  •  go-up   go-down


30. Goldstone AH, Rowe JM: Transplantation in adult ALL. Hematology Am Soc Hematol Educ Program; 2009;:593-601
Genetic Alliance. consumer health - Transplantation.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Transplantation in adult ALL.
  • The value of the allogeneic graft-versus-leukemia effect in adult acute lymphoblastic leukemia (ALL) has now been conclusively demonstrated and confirmed.
  • Patients with the Philadelphia chromosome, those with t(4;11) and those with a complex karyotype remain transplant candidates, and allogeneic transplantation remains the best option for salvage, where achievable, in a remission beyond first.
  • Clinical indications to harness the allogeneic effect will mature as the true value of pediatric protocols in adult patients and the safety and efficacy of a sibling, unrelated and reduced intensity transplant emerge in this disease.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20008244.001).
  • [ISSN] 1520-4383
  • [Journal-full-title] Hematology. American Society of Hematology. Education Program
  • [ISO-abbreviation] Hematology Am Soc Hematol Educ Program
  • [Language] ENG
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Neoplasm Proteins
  • [Number-of-references] 44
  •  go-up   go-down


31. Papi C, Festa V, Leandro G, Moretti A, Tanga M, Koch M, Capurso L: Long-term outcome of Crohn's disease following corticosteroid-induced remission. Am J Gastroenterol; 2007 Apr;102(4):814-9
MedlinePlus Health Information. consumer health - Steroids.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term outcome of Crohn's disease following corticosteroid-induced remission.
  • The aim of the present study was to assess the probability of the need for further steroid treatment in Crohn's disease patients following steroid-induced remission and to establish if clinical variables can predict further steroid needs.
  • PATIENTS AND All METHODS: patients at their first steroid course and with corticosteroid-induced remission, defined as a Crohn's Disease Activity Index (CDAI) <150, 4 wk after steroid weaning, were studied and observed at follow-up for 12 months.
  • RESULTS: A total of 77 patients with steroid-induced remission were included.
  • During follow-up 49 of 75 patients (65.3%) maintained remission or presented mild relapse not requiring steroids while 26 of 75 patients (34.6%) had moderate to severe relapse requiring further steroid treatment.
  • An increased C reactive protein value, at steroid weaning, despite clinical remission, and penetrating complications may predict further steroid requirement in already steroid responsive patients.
  • [MeSH-minor] Administration, Oral. Adult. C-Reactive Protein / analysis. Female. Humans. Male. Middle Aged. Proportional Hazards Models. Recurrence. Remission Induction. Retrospective Studies. Treatment Outcome

  • Genetic Alliance. consumer health - Crohn Disease.
  • MedlinePlus Health Information. consumer health - Crohn's Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17222316.001).
  • [ISSN] 0002-9270
  • [Journal-full-title] The American journal of gastroenterology
  • [ISO-abbreviation] Am. J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adrenal Cortex Hormones; 9007-41-4 / C-Reactive Protein
  •  go-up   go-down


32. Rolfe VE, Fortun PJ, Hawkey CJ, Bath-Hextall F: Probiotics for maintenance of remission in Crohn's disease. Cochrane Database Syst Rev; 2006;(4):CD004826
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Probiotics for maintenance of remission in Crohn's disease.
  • BACKGROUND: Crohn's disease (CD) is characterised by episodes of disease activity and symptom-free remission.
  • OBJECTIVES: To assess the effectiveness of probiotics for the maintenance of remission in CD.
  • There was no statistically significant benefit of E. coli Nissle for reducing the risk of relapse compared to placebo (RR 0.43, 95% CI 0.15 to 1.20), or Lactobacillus GG after surgically-induced remission (RR 1.58, 95% CI 0.30 to 8.40) or medically-induced remission (RR 0.83, 95% CI 0.25 to 2.80).
  • AUTHORS' CONCLUSIONS: There is no evidence to suggest that probiotics are beneficial for the maintenance of remission in CD.
  • [MeSH-minor] Adult. Child. Humans. Randomized Controlled Trials as Topic. Remission Induction

  • Genetic Alliance. consumer health - Crohn Disease.
  • MedlinePlus Health Information. consumer health - Crohn's Disease.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17054217.001).
  • [ISSN] 1469-493X
  • [Journal-full-title] The Cochrane database of systematic reviews
  • [ISO-abbreviation] Cochrane Database Syst Rev
  • [Language] eng
  • [Publication-type] Journal Article; Meta-Analysis; Review
  • [Publication-country] England
  • [Number-of-references] 50
  •  go-up   go-down


33. Fujita H, Nakaya A, Kato J, Tachibana T, Takemura S, Hyo R, Kawano T, Tanaka M, Taguchi J, Maruta A, Fujimaki K, Kanamori H, Ishigatsubo Y: [Hematopoietic stem cell transplantation in the second or later complete remission in acute promyelocytic leukemia initially treated with all-trans retinoic acid]. Rinsho Ketsueki; 2005 Oct;46(10):1095-9
Hazardous Substances Data Bank. ALL-TRANS-RETINOIC ACID .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Hematopoietic stem cell transplantation in the second or later complete remission in acute promyelocytic leukemia initially treated with all-trans retinoic acid].
  • Despite the use of all-trans retinoic acid (ATRA) as the first-line treatment for acute promyelocytic leukemia (APL), relapse occurs in about 20% of cases.
  • Most relapsing APL patients can achieve second remission (CR2) following ATRA combined with chemotherapy or arsenic trioxide.
  • Complete molecular remission has been maintained in the remaining 2 patients.
  • Complete molecular remission has been maintained in all 4 patients (mean follow-up, 3 years 9 months).
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Hematopoietic Stem Cell Transplantation. Leukemia, Promyelocytic, Acute / therapy. Tretinoin / therapeutic use
  • [MeSH-minor] Adult. Combined Modality Therapy. Female. Humans. Male. Middle Aged. Neoplasm Recurrence, Local. Remission Induction. Retrospective Studies. Treatment Outcome

  • Genetic Alliance. consumer health - Acute Promyelocytic Leukemia.
  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16440769.001).
  • [ISSN] 0485-1439
  • [Journal-full-title] [Rinshō ketsueki] The Japanese journal of clinical hematology
  • [ISO-abbreviation] Rinsho Ketsueki
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 5688UTC01R / Tretinoin
  •  go-up   go-down


34. Mantzaris GJ, Roussos A, Kalantzis C, Koilakou S, Raptis N, Kalantzis N: How adherent to treatment with azathioprine are patients with Crohn's disease in long-term remission? Inflamm Bowel Dis; 2007 Apr;13(4):446-50
Hazardous Substances Data Bank. AZATHIOPRINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] How adherent to treatment with azathioprine are patients with Crohn's disease in long-term remission?
  • The aim of the present study was to assess the adherence to azathioprine in a cohort of patients with Crohn's disease in long-term remission.
  • METHODS: Thirty patients with Crohn's disease in remission on azathioprine for > or =48 months were enrolled in the study.
  • CONCLUSIONS: Most patients with Crohn's disease in longstanding remission had low self-reported adherence to azathioprine.
  • Patients considered nonadherent to treatment maintained disease remission and a quality of life similar to patients who were adherent to treatment.
  • [MeSH-minor] Adult. Female. Humans. Longitudinal Studies. Male. Quality of Life. Risk Factors

  • Genetic Alliance. consumer health - Crohn Disease.
  • MedlinePlus Health Information. consumer health - Crohn's Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17206674.001).
  • [ISSN] 1078-0998
  • [Journal-full-title] Inflammatory bowel diseases
  • [ISO-abbreviation] Inflamm. Bowel Dis.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites; MRK240IY2L / Azathioprine
  •  go-up   go-down


35. Sandborn WJ, Löfberg R, Feagan BG, Hanauer SB, Campieri M, Greenberg GR: Budesonide for maintenance of remission in patients with Crohn's disease in medically induced remission: a predetermined pooled analysis of four randomized, double-blind, placebo-controlled trials. Am J Gastroenterol; 2005 Aug;100(8):1780-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Budesonide for maintenance of remission in patients with Crohn's disease in medically induced remission: a predetermined pooled analysis of four randomized, double-blind, placebo-controlled trials.
  • OBJECTIVES: To evaluate the efficacy and safety of oral budesonide for maintenance of remission in patients with mild to moderately active Crohn's disease (CD) of the ileum and/or ascending colon.
  • Three hundred eighty patients with CD in medically induced remission (CD activity index [CDAI]< or =150) were randomized to receive oral budesonide 3 mg, 6 mg, or placebo daily for 12 months.
  • CONCLUSION: Budesonide 6 mg/day is effective for prolonging time to relapse and for significantly reducing rates of relapse at 3 and 6 months but not 12 months in patients with CD in medically induced remission.
  • [MeSH-minor] Adolescent. Adult. Aged. Double-Blind Method. Female. Humans. Male. Middle Aged. Recurrence. Remission Induction. Treatment Outcome

  • Genetic Alliance. consumer health - Crohn Disease.
  • MedlinePlus Health Information. consumer health - Crohn's Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16086715.001).
  • [ISSN] 0002-9270
  • [Journal-full-title] The American journal of gastroenterology
  • [ISO-abbreviation] Am. J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study; Randomized Controlled Trial
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents; 51333-22-3 / Budesonide
  •  go-up   go-down


36. Rowe JM: Optimal induction and post-remission therapy for AML in first remission. Hematology Am Soc Hematol Educ Program; 2009;:396-405
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Optimal induction and post-remission therapy for AML in first remission.
  • Approximately 300,000 patients in the world are diagnosed annually with acute myeloid leukemia (AML).
  • The therapy of AML, unlike acute lymphoblastic leukemia (ALL), is based on maximally tolerated induction and post-remission therapy, all given within a few months from diagnosis.
  • While complete remission can be achieved in the majority of young patients, ultimate cure of the disease depends on disease eradication through the administration of post-remission therapy.
  • Harnessing the immunologic effect of graft-versus-leukemia, as in allogeneic transplantation, has further improved the outcome for many patients.
  • While 40% to 50% can achieve a complete remission, less than 10% are long-term survivors, and the cure rate of older patients has only minimally improved over the past three decades.

  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. DAUNORUBICIN .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20008225.001).
  • [ISSN] 1520-4383
  • [Journal-full-title] Hematology. American Society of Hematology. Education Program
  • [ISO-abbreviation] Hematology Am Soc Hematol Educ Program
  • [Language] ENG
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; ZS7284E0ZP / Daunorubicin
  • [Number-of-references] 41
  •  go-up   go-down


37. Wang GJ, Li W, Cui JW, Gao SJ, Yao C, Jiang ZY, Song YQ, Yuan CJ, Yang Y, Liu ZL: [Therapeutic effects of combination of arsenic trioxide with low-dose all-trans retinoic acid on induction of remission acute promyeloeytic leukemia]. Zhonghua Yi Xue Za Zhi; 2005 Apr 27;85(16):1093-6
Hazardous Substances Data Bank. ALL-TRANS-RETINOIC ACID .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Therapeutic effects of combination of arsenic trioxide with low-dose all-trans retinoic acid on induction of remission acute promyeloeytic leukemia].
  • OBJECTIVE: To observe the therapeutic efficacy and side effects of arsenic trioxide (As2O3)combined with low-dose all-trans retinoic acid (ATRA) on remission induction in newly-diagnosed and relapsed patients with acute promyeloeytic leukemia (APL).
  • The complete remission (CR) rate, period to CR, incidence of early death and side effects were observed in the three groups.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Leukemia, Promyelocytic, Acute / drug therapy
  • [MeSH-minor] Adolescent. Adult. Arsenicals / administration & dosage. Drug Administration Schedule. Female. Humans. Male. Middle Aged. Oxides / administration & dosage. Remission Induction. Treatment Outcome. Tretinoin / administration & dosage

  • Hazardous Substances Data Bank. ARSENIC TRIOXIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16029564.001).
  • [ISSN] 0376-2491
  • [Journal-full-title] Zhonghua yi xue za zhi
  • [ISO-abbreviation] Zhonghua Yi Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Arsenicals; 0 / Oxides; 5688UTC01R / Tretinoin; S7V92P67HO / arsenic trioxide
  •  go-up   go-down


38. Mäkinen H, Kautiainen H, Hannonen P, Sokka T: Is DAS28 an appropriate tool to assess remission in rheumatoid arthritis? Ann Rheum Dis; 2005 Oct;64(10):1410-3
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Is DAS28 an appropriate tool to assess remission in rheumatoid arthritis?
  • OBJECTIVES: To study which cut off point of DAS28 corresponds to fulfilment of the American Rheumatism Association (ARA) preliminary remission criteria, and clinical remission criteria in patients with rheumatoid arthritis (RA).
  • METHODS: All adult patients diagnosed with RA at Jyväskylä Central Hospital 1997-98 were assessed for remission at 5 years.
  • Remission was defined as (a) ARA remission;.
  • (b) clinical remission (defined as no tender or swollen joints and normal erythrocyte sedimentation rate).
  • A receiver operating characteristics curve analysis was performed to calculate a cut off point of DAS28 that best corresponds to the ARA remission criteria and the clinical remission criteria.
  • At 5 years, 19 (12%) patients met the ARA remission criteria, and 55 (34%) met the clinical remission criteria.
  • The cut off value of DAS28 was 2.32 for the ARA remission criteria, and 2.68 for the clinical remission criteria.
  • CONCLUSION: In this study the DAS28 cut off point for the ARA remission was lower than in previous studies.
  • The cut off point for DAS28 remission remains controversial.
  • A substantial proportion of patients below the DAS28 cut off point for remission have tender or swollen joints, or both.
  • DAS28 may not be an appropriate tool for assessment of remission in RA.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Blood Sedimentation. Female. Humans. Male. Middle Aged. Predictive Value of Tests. ROC Curve. Remission Induction. Treatment Outcome


39. Bidot CJ, Jy W, Horstman LL, Ahn ER, Jimenez JJ, Yaniz M, Lander G, Ahn YS: Antiphospholipid antibodies in immune thrombocytopenic purpura tend to emerge in exacerbation and decline in remission. Br J Haematol; 2005 Feb;128(3):366-72
MedlinePlus Health Information. consumer health - Autoimmune Diseases.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Antiphospholipid antibodies in immune thrombocytopenic purpura tend to emerge in exacerbation and decline in remission.
  • We studied APLA in 40 patients in three stages of ITP: exacerbation/relapse (n=7), stable (n=14) and remission (n=19).
  • The central finding was that APLA were common in ITP but differed significantly in disease stages, being highest in exacerbation (86% positive), intermediate in stable disease (57%) and lowest in remission (42%).
  • During remission, APLA often became undetectable.
  • Both the frequency and titres of APLA were significantly higher during exacerbation than remission.
  • Sequential study of six patients revealed that APLA tended to emerge and rise with exacerbation, concurrently with new episodes of bleeding and became undetectable during remission.
  • These findings raise the possibility that APLA may play a role in the exacerbation and remission of ITP or they may be a consequence of platelet destruction.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Autoantigens / immunology. Female. Humans. Immunoglobulin G / blood. Immunoglobulin M / blood. Male. Middle Aged. Platelet Count. Recurrence. Remission Induction

  • Genetic Alliance. consumer health - Immune Thrombocytopenic Purpura.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15667539.001).
  • [ISSN] 0007-1048
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Antiphospholipid; 0 / Autoantigens; 0 / Immunoglobulin G; 0 / Immunoglobulin M
  •  go-up   go-down


40. Marisavljević D, Rolović Z, Ludoski-Pantić M, Djordjević V, Novak A: Spontaneous remission in adults with primary myelodysplastic syndromes: incidence and characteristics of patients. Med Oncol; 2005;22(4):407-10
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Spontaneous remission in adults with primary myelodysplastic syndromes: incidence and characteristics of patients.
  • We report five adult patients with spontaneous remission of MDS, achieved without cytotoxic or any other treatment.
  • Median time to complete hematological and cytogenetical remission was 51 mo, while median duration of spontaneous remission was 45 mo (range 44-60 mo).
  • [MeSH-minor] Adult. Aged. Bone Marrow Cells / pathology. Cytogenetic Analysis. Female. Humans. Middle Aged. Remission, Spontaneous


41. Sanli H, Akay BN, Ayyildiz E, Anadolu R, Ilhan O: Remission of severe autoimmune bullous disorders induced by long-term extracorporeal photochemotherapy. Transfus Apher Sci; 2010 Dec;43(3):353-9
Hazardous Substances Data Bank. PREDNISOLONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Remission of severe autoimmune bullous disorders induced by long-term extracorporeal photochemotherapy.
  • In drug-resistant cases, adjuvant treatment with extracorporeal photochemotherapy (ECP) has been reported to induce remission.
  • The treatment has produced a remarkable corticosteroid-sparing effect while inducing clinical remission.
  • [MeSH-minor] Adult. Autoimmune Diseases / therapy. Drug Resistance. Female. Humans. Male. Middle Aged. Prednisolone / therapeutic use. Remission Induction / methods. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Pemphigus.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Ltd. All rights reserved.
  • (PMID = 21035398.001).
  • [ISSN] 1473-0502
  • [Journal-full-title] Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis
  • [ISO-abbreviation] Transfus. Apher. Sci.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 9PHQ9Y1OLM / Prednisolone
  •  go-up   go-down


42. Rosa AR, Reinares M, Franco C, Comes M, Torrent C, Sánchez-Moreno J, Martínez-Arán A, Salamero M, Kapczinski F, Vieta E: Clinical predictors of functional outcome of bipolar patients in remission. Bipolar Disord; 2009 Jun;11(4):401-9
MedlinePlus Health Information. consumer health - Bipolar Disorder.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical predictors of functional outcome of bipolar patients in remission.
  • CONCLUSIONS: A substantial proportion of bipolar patients experience unfavorable functioning, suggesting that there is a significant degree of morbidity and dysfunction associated with BD, even during remission periods.
  • [MeSH-minor] Activities of Daily Living. Adult. Cognition Disorders / etiology. Employment. Female. Financing, Personal. Follow-Up Studies. Humans. Interpersonal Relations. Male. Middle Aged. Neuropsychological Tests. Personal Autonomy. Predictive Value of Tests. Psychiatric Status Rating Scales. Recurrence. Surveys and Questionnaires

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19500093.001).
  • [ISSN] 1399-5618
  • [Journal-full-title] Bipolar disorders
  • [ISO-abbreviation] Bipolar Disord
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Denmark
  •  go-up   go-down


43. Balighi K, Taheri A, Mansoori P, Chams C: Value of direct immunofluorescence in predicting remission in pemphigus vulgaris. Int J Dermatol; 2006 Nov;45(11):1308-11
MedlinePlus Health Information. consumer health - Pemphigus.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Value of direct immunofluorescence in predicting remission in pemphigus vulgaris.
  • Multiple relapses and remission may occur during the course of the disease.
  • The goal of this study was to determine whether direct immunofluorescence study has any value in detecting immunological remission of pemphigus vulgaris.
  • METHODS: Fifty-seven patients with pemphigus vulgaris who were in clinical remission for at least 3 months, while taking prednisolone 5-7.5 mg/day, were recruited retrospectively for the study.
  • Direct immunofluorescence study had been performed in all patients after a period of at least 3 months in clinical remission.
  • RESULTS: Of 57 patients who were in clinical remission, 24 patients (42%) had negative and 33 patients (58%) had positive results of direct immunofluorescence.
  • Nine patients with negative direct immunofluorescence had a history of more than 6 months of clinical remission before direct immunofluorescence study.
  • None of four patients with history of more than 12 months of clinical remission before a negative direct immunofluorescence study relapsed.
  • CONCLUSIONS: Negative direct immunofluorescence is an indicator of immunological remission in patients with pemphigus vulgaris after 6-12 months in clinical remission.
  • [MeSH-minor] Adult. Aged. Animals. Female. Humans. Male. Middle Aged. Prognosis. Remission Induction. Reproducibility of Results. Retrospective Studies. Skin / drug effects. Skin / pathology. Time Factors

  • Genetic Alliance. consumer health - Pemphigus.
  • Genetic Alliance. consumer health - Pemphigus vulgaris.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17076711.001).
  • [ISSN] 0011-9059
  • [Journal-full-title] International journal of dermatology
  • [ISO-abbreviation] Int. J. Dermatol.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


44. Ribera JM, Oriol A, Bethencourt C, Parody R, Hernández-Rivas JM, Moreno MJ, del Potro E, Torm M, Rivas C, Besalduch J, Sanz MA, Ortega JJ, PETHEMA Group, Spain: Comparison of intensive chemotherapy, allogeneic or autologous stem cell transplantation as post-remission treatment for adult patients with high-risk acute lymphoblastic leukemia. Results of the PETHEMA ALL-93 trial. Haematologica; 2005 Oct;90(10):1346-56
Genetic Alliance. consumer health - Transplantation.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparison of intensive chemotherapy, allogeneic or autologous stem cell transplantation as post-remission treatment for adult patients with high-risk acute lymphoblastic leukemia. Results of the PETHEMA ALL-93 trial.
  • BACKGROUND AND OBJECTIVES: The optimal post-remission therapy for adults with high-risk acute lymphoblastic leukemia (ALL) is not well established.
  • This multicenter randomized trial by the Spanish PETHEMA Group was addressed to compare three options of post-remission therapy in adults with high-risk ALL: chemotherapy, allogeneic stem cell transplantation (SCT) and autologous SCT.
  • Patients in complete remission with an HLA-identical family donor were assigned to allogeneic SCT (n=84) and the remaining were randomized to autologous SCT (n=50) or to delayed intensification followed by maintenance chemotherapy up to 2 years in complete remission (n=48).
  • RESULTS: Overall, 183 patients achieved complete remission (82%).
  • [MeSH-major] Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / surgery. Stem Cell Transplantation / methods
  • [MeSH-minor] Adolescent. Adult. Antineoplastic Agents / therapeutic use. Disease-Free Survival. Female. Follow-Up Studies. Humans. Male. Middle Aged. Remission Induction. Risk Factors. Transplantation, Autologous. Transplantation, Homologous

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Haematologica. 2005 Oct;90(10):1299 [16219555.001]
  • (PMID = 16219571.001).
  • [ISSN] 1592-8721
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


45. Taylor DR, Cowan JO, Greene JM, Willan AR, Sears MR: Asthma in remission: can relapse in early adulthood be predicted at 18 years of age? Chest; 2005 Mar;127(3):845-50
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Asthma in remission: can relapse in early adulthood be predicted at 18 years of age?
  • STUDY OBJECTIVE: To determine the frequency of relapse of asthma in young adults in remission at 18 years of age, during a follow-up period of 8 years, and to identify possible prognostic markers for relapse.
  • RESULTS: Approximately one third of study members (35%) with asthma in remission at 18 years of age relapsed by 21 years or 26 years of age.
  • Totally new adult asthma developed by 26 years of age in 9% of study members who had no asthma or wheezing at any time up to 18 years of age.
  • CONCLUSIONS: Subsequent relapse of previously diagnosed asthma in remission at 18 years of age occurs in one in three young adults.
  • A history of asthma currently in remission should not be used to prejudice employment opportunities for young adults.
  • [MeSH-minor] Adolescent. Adult. Bronchial Hyperreactivity. Bronchial Provocation Tests. Female. Forced Expiratory Volume. Humans. Male. Prognosis. Recurrence. Vital Capacity

  • Genetic Alliance. consumer health - Asthma.
  • MedlinePlus Health Information. consumer health - Asthma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15764766.001).
  • [ISSN] 0012-3692
  • [Journal-full-title] Chest
  • [ISO-abbreviation] Chest
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


46. Jahanlu D, Hunskaar S: The Hordaland Women's Cohort: prevalence, incidence, and remission of urinary incontinence in middle-aged women. Int Urogynecol J; 2010 Oct;21(10):1223-9
MedlinePlus Health Information. consumer health - Urinary Incontinence.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The Hordaland Women's Cohort: prevalence, incidence, and remission of urinary incontinence in middle-aged women.
  • INTRODUCTION AND HYPOTHESIS: The aim of study is to prospectively investigate the prevalence, incidence, and remission of urinary incontinence (UI) in a cohort of middle-aged women.
  • There was then a decrease in prevalence caused by a decrease in incidence and decrease in remission.
  • [MeSH-minor] Adult. Cohort Studies. Female. Humans. Incidence. Middle Aged. Prevalence. Prospective Studies. Remission Induction

  • Genetic Alliance. consumer health - Incontinence.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20449565.001).
  • [ISSN] 1433-3023
  • [Journal-full-title] International urogynecology journal
  • [ISO-abbreviation] Int Urogynecol J
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


47. Terwey TH, Massenkeil G, Tamm I, Hemmati PG, Neuburger S, Martus P, Dörken B, Hoelzer D, Arnold R: Allogeneic SCT in refractory or relapsed adult ALL is effective without prior reinduction chemotherapy. Bone Marrow Transplant; 2008 Dec;42(12):791-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Allogeneic SCT in refractory or relapsed adult ALL is effective without prior reinduction chemotherapy.
  • We present 60 patients with refractory (n=8) or relapsed (n=52) adult ALL who received allogeneic hematopoietic SCT (HSCT) with (n=41) or without (n=19) prior reinduction chemotherapy.
  • Leukemia-free survival at 1, 2 and 5 years was 37, 33 and 24%.
  • Deaths were due to relapse (n=25), acute or chronic GVHD (n=7), infections (n=8) or toxicity (n=4).
  • [MeSH-major] Hematopoietic Stem Cell Transplantation. Neoplasm Recurrence, Local / therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy. Transplantation Conditioning / methods
  • [MeSH-minor] Adolescent. Adult. Drug Resistance, Neoplasm. Drug Therapy / utilization. Female. Humans. Male. Middle Aged. Remission Induction. Retrospective Studies. Survival Analysis. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18711350.001).
  • [ISSN] 1476-5365
  • [Journal-full-title] Bone marrow transplantation
  • [ISO-abbreviation] Bone Marrow Transplant.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


48. Lucas A, Cobelens PM, Kavelaars A, Heijnen CJ, Holtmann G, Haag S, Gerken G, Langhorst J, Dobos GJ, Schedlowski M, Elsenbruch S: Disturbed in vitro adrenergic modulation of cytokine production in inflammatory bowel diseases in remission. J Neuroimmunol; 2007 Jan;182(1-2):195-203
Hazardous Substances Data Bank. DEXAMETHASONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Disturbed in vitro adrenergic modulation of cytokine production in inflammatory bowel diseases in remission.
  • METHODS: We analyzed the in vitro effects of the beta-adrenergic agonist terbutaline and the glucocorticoid agonist dexamethasone on TNF-alpha and IL-10 production by LPS-stimulated monocytes in whole cell blood cultures in patients with inflammatory bowel diseases in remission (N=10), diarrhoea-predominant irritable bowel syndrome (IBS, N=12), patients with a recent gastroenteritis (post-infectious group, N=10), and healthy controls (N=15).
  • [MeSH-minor] Adult. Dexamethasone / administration & dosage. Dexamethasone / pharmacology. Diarrhea / etiology. Dose-Response Relationship, Drug. Gastroenteritis / blood. Gastroenteritis / microbiology. Glucocorticoids / administration & dosage. Glucocorticoids / pharmacology. Humans. In Vitro Techniques. Infection. Lipopolysaccharides / pharmacology. Middle Aged. Remission Induction

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17112600.001).
  • [ISSN] 0165-5728
  • [Journal-full-title] Journal of neuroimmunology
  • [ISO-abbreviation] J. Neuroimmunol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Adrenergic beta-Agonists; 0 / Glucocorticoids; 0 / Lipopolysaccharides; 0 / Tumor Necrosis Factor-alpha; 130068-27-8 / Interleukin-10; 7S5I7G3JQL / Dexamethasone; N8ONU3L3PG / Terbutaline
  •  go-up   go-down


49. Naganuma M, Sakuraba A, Hisamatsu T, Ochiai H, Hasegawa H, Ogata H, Iwao Y, Hibi T: Efficacy of infliximab for induction and maintenance of remission in intestinal Behçet's disease. Inflamm Bowel Dis; 2008 Sep;14(9):1259-64
Hazardous Substances Data Bank. Infliximab .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Efficacy of infliximab for induction and maintenance of remission in intestinal Behçet's disease.
  • Although several cases have been reported that infliximab is effective for induction of remission, the efficacy of infliximab for maintaining remission is unknown.
  • RESULTS: Four patients achieved remission by infliximab and all of these patients maintained remission with scheduled treatments of infliximab, with the longest duration of remission being about 3 years.
  • Another 2 patients with ileal ulceration required surgery; however, 1 patient has maintained remission by scheduled treatment of infliximab for 2 years after surgery.
  • CONCLUSIONS: Infliximab appears to offer an option for fulminant intestinal BD to induce and maintain remission, although a randomized control trial is needed.
  • [MeSH-minor] Adult. Colonoscopy. Female. Humans. Infliximab. Male. Middle Aged. Remission Induction. Treatment Outcome

  • Genetic Alliance. consumer health - Behcet's Disease.
  • MedlinePlus Health Information. consumer health - Behcet's Syndrome.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Inflamm Bowel Dis. 2009 Dec;15(12):1769-71 [19177427.001]
  • (PMID = 18393375.001).
  • [ISSN] 1536-4844
  • [Journal-full-title] Inflammatory bowel diseases
  • [ISO-abbreviation] Inflamm. Bowel Dis.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Gastrointestinal Agents; B72HH48FLU / Infliximab
  •  go-up   go-down


50. Goldstone AH, Richards SM, Lazarus HM, Tallman MS, Buck G, Fielding AK, Burnett AK, Chopra R, Wiernik PH, Foroni L, Paietta E, Litzow MR, Marks DI, Durrant J, McMillan A, Franklin IM, Luger S, Ciobanu N, Rowe JM: In adults with standard-risk acute lymphoblastic leukemia, the greatest benefit is achieved from a matched sibling allogeneic transplantation in first complete remission, and an autologous transplantation is less effective than conventional consolidation/maintenance chemotherapy in all patients: final results of the International ALL Trial (MRC UKALL XII/ECOG E2993). Blood; 2008 Feb 15;111(4):1827-33
Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] In adults with standard-risk acute lymphoblastic leukemia, the greatest benefit is achieved from a matched sibling allogeneic transplantation in first complete remission, and an autologous transplantation is less effective than conventional consolidation/maintenance chemotherapy in all patients: final results of the International ALL Trial (MRC UKALL XII/ECOG E2993).
  • An international collaboration was set up to prospectively evaluate the role of allogeneic transplantation for adults with acute lymphoblastic leukemia (ALL) and compare autologous transplantation with standard chemotherapy.
  • Patients received 2 phases of induction and, if in remission, were assigned to allogeneic transplantation if they had a compatible sibling donor.
  • Matched related allogeneic transplantations for ALL in first complete remission provide the most potent antileukemic therapy and considerable survival benefit for standard-risk patients.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy
  • [MeSH-minor] Adolescent. Adult. Disease-Free Survival. Humans. Middle Aged. Recurrence. Risk Factors. Siblings. Survival Analysis. Transplantation, Autologous. Transplantation, Homologous


51. Minderhoud IM, Oldenburg B, Schipper ME, ter Linde JJ, Samsom M: Serotonin synthesis and uptake in symptomatic patients with Crohn's disease in remission. Clin Gastroenterol Hepatol; 2007 Jun;5(6):714-20
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Serotonin synthesis and uptake in symptomatic patients with Crohn's disease in remission.
  • BACKGROUND & AIMS: Symptoms resembling irritable bowel syndrome (IBS) are reported frequently in Crohn's disease (CD) patients in remission.
  • We aimed to study the role of serotonin in the generation of IBS-like symptoms in CD patients in remission.
  • METHODS: Ileal and colonic biopsy specimens were obtained from 20 CD patients in remission, 10 with and 10 without IBS-like symptoms, and 11 healthy controls.
  • CONCLUSIONS: CD patients in remission who experience IBS-like symptoms have increased mucosal TpH-1 levels in the colon, suggesting that increased serotonin biosynthesis in the colon plays a role in the generation of the symptoms.
  • [MeSH-minor] Adult. Cell Count. Colon / pathology. Colonoscopy. Enterochromaffin Cells / cytology. Enteroendocrine Cells / cytology. Female. Humans. Ileum / pathology. Irritable Bowel Syndrome / metabolism. Male. RNA, Messenger / metabolism. Remission Induction. Serotonin Plasma Membrane Transport Proteins / metabolism. Tryptophan Hydroxylase / metabolism

  • Genetic Alliance. consumer health - Crohn Disease.
  • MedlinePlus Health Information. consumer health - Crohn's Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17481962.001).
  • [ISSN] 1542-7714
  • [Journal-full-title] Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
  • [ISO-abbreviation] Clin. Gastroenterol. Hepatol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / RNA, Messenger; 0 / Serotonin Plasma Membrane Transport Proteins; 333DO1RDJY / Serotonin; EC 1.14.16.4 / Tryptophan Hydroxylase
  •  go-up   go-down


52. Nemeroff CB, Entsuah R, Benattia I, Demitrack M, Sloan DM, Thase ME: Comprehensive analysis of remission (COMPARE) with venlafaxine versus SSRIs. Biol Psychiatry; 2008 Feb 15;63(4):424-34
Hazardous Substances Data Bank. SERTRALINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comprehensive analysis of remission (COMPARE) with venlafaxine versus SSRIs.
  • The primary outcome measure was intent-to-treat (ITT) remission rates (Hamilton Rating Scale for Depression </=7) at week 8.
  • RESULTS: The overall difference in ITT remission rates was 5.9% favoring venlafaxine (95% confidence interval [CI]: .038-.081; p < .001).
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Citalopram / therapeutic use. Female. Fluoxetine / therapeutic use. Fluvoxamine / therapeutic use. Humans. Male. Middle Aged. Paroxetine / therapeutic use. Randomized Controlled Trials as Topic. Remission Induction. Sertraline / therapeutic use. Venlafaxine Hydrochloride

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. PAROXETINE HYDROCHLORIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Biol Psychiatry. 2009 Sep 1;66(5):e7; authour reply e9-10 [19520365.001]
  • (PMID = 17888885.001).
  • [ISSN] 1873-2402
  • [Journal-full-title] Biological psychiatry
  • [ISO-abbreviation] Biol. Psychiatry
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Meta-Analysis; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cyclohexanols; 0 / Serotonin Uptake Inhibitors; 01K63SUP8D / Fluoxetine; 0DHU5B8D6V / Citalopram; 41VRH5220H / Paroxetine; 7D7RX5A8MO / Venlafaxine Hydrochloride; O4L1XPO44W / Fluvoxamine; QUC7NX6WMB / Sertraline
  •  go-up   go-down


53. Lemke H, de Castro AG, Schlattmann P, Heuser I, Neu P: Cerebrovascular reactivity over time-course - from major depressive episode to remission. J Psychiatr Res; 2010 Feb;44(3):132-6
Hazardous Substances Data Bank. ACETAZOLAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cerebrovascular reactivity over time-course - from major depressive episode to remission.
  • We hypothesized that CVR might be continuously reduced in patients with major depression even after successful remission thus contributing to the association between depression and stroke.
  • MATERIALS AND METHODS: We investigated CVR in a group of patients (N=29) in the acute episode of depressive illness and after 21months under euthymic condition.
  • On follow-up 21months later after treatment and remission, CVR in the patient group had significantly improved, whereas CVR in the control group remained unchanged.
  • [MeSH-minor] Acetazolamide / pharmacology. Adolescent. Adult. Aged. Anticonvulsants / pharmacology. Blood Flow Velocity / drug effects. Female. Humans. Male. Middle Aged. Remission Induction. Risk Factors. Stroke / etiology. Young Adult

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 Elsevier Ltd. All rights reserved.
  • (PMID = 19656526.001).
  • [ISSN] 1879-1379
  • [Journal-full-title] Journal of psychiatric research
  • [ISO-abbreviation] J Psychiatr Res
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Anticonvulsants; O3FX965V0I / Acetazolamide
  •  go-up   go-down


54. Chung KH, Tsai SY: Hyperinsulinemia associated with overweight medicated bipolar patients during full remission. Psychiatry Clin Neurosci; 2010 Dec;64(6):620-4
Hazardous Substances Data Bank. CHOLESTEROL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hyperinsulinemia associated with overweight medicated bipolar patients during full remission.
  • Acute medicated bipolar patients are vulnerable to hyperinsulinemia in early remission.
  • METHODS: Measurements taken in this study included the fasting plasma levels of insulin, glucose, triglycerides, total cholesterol, high-density-lipoprotein-cholesterol, low-density-lipoprotein-cholesterol, and the body mass index (BMI) among 56 bipolar I manic patients in full remission.
  • [MeSH-minor] Adult. Antimanic Agents / therapeutic use. Antipsychotic Agents / therapeutic use. Blood Glucose / metabolism. Body Mass Index. Cholesterol / blood. Fasting / blood. Female. Humans. Insulin / blood. Male. Remission Induction. Triglycerides / blood

  • MedlinePlus Health Information. consumer health - Bipolar Disorder.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2010 The Authors. Psychiatry and Clinical Neurosciences © 2010 Japanese Society of Psychiatry and Neurology.
  • (PMID = 21040189.001).
  • [ISSN] 1440-1819
  • [Journal-full-title] Psychiatry and clinical neurosciences
  • [ISO-abbreviation] Psychiatry Clin. Neurosci.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Antimanic Agents; 0 / Antipsychotic Agents; 0 / Blood Glucose; 0 / Insulin; 0 / Triglycerides; 97C5T2UQ7J / Cholesterol
  •  go-up   go-down


55. Kaya E, Aydemir O, Selcuki D: Residual symptoms in bipolar disorder: the effect of the last episode after remission. Prog Neuropsychopharmacol Biol Psychiatry; 2007 Oct 1;31(7):1387-92
MedlinePlus Health Information. consumer health - Bipolar Disorder.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Residual symptoms in bipolar disorder: the effect of the last episode after remission.
  • All patients were in remission for at least 6 months.
  • [MeSH-minor] Adolescent. Adult. Affect / physiology. Aged. Aged, 80 and over. Antimanic Agents / therapeutic use. Antipsychotic Agents / therapeutic use. Cognition / physiology. Cognition Disorders / psychology. Depressive Disorder / psychology. Event-Related Potentials, P300 / physiology. Female. Humans. Male. Middle Aged. Neuropsychological Tests. Psychiatric Status Rating Scales. Social Adjustment. Social Behavior. Verbal Learning / physiology

  • Genetic Alliance. consumer health - Bipolar Disorder.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17628288.001).
  • [ISSN] 0278-5846
  • [Journal-full-title] Progress in neuro-psychopharmacology & biological psychiatry
  • [ISO-abbreviation] Prog. Neuropsychopharmacol. Biol. Psychiatry
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antimanic Agents; 0 / Antipsychotic Agents
  •  go-up   go-down


56. Csepregi A, Röcken C, Treiber G, Malfertheiner P: Budesonide induces complete remission in autoimmune hepatitis. World J Gastroenterol; 2006 Mar 7;12(9):1362-6
Genetic Alliance. consumer health - Autoimmune Hepatitis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Budesonide induces complete remission in autoimmune hepatitis.
  • However, only 65% of the patients enter complete histological remission.
  • RESULTS: Fifteen (83%) patients had a complete clinical and biochemical remission.
  • Ten patients, including five with acute hepatitis,were given BUD as first-line therapy, of which seven enter remission.
  • Three patients, two with liver cirrhosis, did not improve.All patients with second-line therapy experienced long-term remission.
  • A histological remission was also seen in three patients.
  • CONCLUSION: BUD is effective in remission induction in the majority of our patients with AIH.
  • [MeSH-minor] Adult. Aged. Female. Humans. Liver / pathology. Liver Cirrhosis / drug therapy. Liver Cirrhosis / pathology. Male. Middle Aged. Remission Induction. Salvage Therapy

  • Genetic Alliance. consumer health - Hepatitis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Hepatol. 1999 Nov;31(5):929-38 [10580593.001]
  • [Cites] Gastroenterology. 2000 Nov;119(5):1312-6 [11054389.001]
  • [Cites] Gastroenterology. 2001 May;120(6):1502-17 [11313321.001]
  • [Cites] Hepatology. 2003 Jul;38(1):196-202 [12830002.001]
  • [Cites] Hepatology. 2005 Jan;41(1):207-15 [15690485.001]
  • [Cites] Acta Derm Venereol Suppl (Stockh). 1989;151:11-9; discussion 47-52 [2624062.001]
  • [Cites] Aliment Pharmacol Ther. 1994 Dec;8(6):585-90 [7696446.001]
  • [Cites] J Hepatol. 1995 Jun;22(6):696-9 [7560864.001]
  • [Cites] Drugs. 1984 Dec;28(6):485-518 [6394263.001]
  • (PMID = 16552802.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents; 51333-22-3 / Budesonide
  • [Other-IDs] NLM/ PMC4124311
  •  go-up   go-down


57. Wiroth JB, Filippi J, Schneider SM, Al-Jaouni R, Horvais N, Gavarry O, Bermon S, Hébuterne X: Muscle performance in patients with Crohn's disease in clinical remission. Inflamm Bowel Dis; 2005 Mar;11(3):296-303
MedlinePlus Health Information. consumer health - Crohn's Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Muscle performance in patients with Crohn's disease in clinical remission.
  • This study aimed to assess muscle strength and endurance in CD patients in clinical remission and the influencing factors.
  • METHODS: Forty-one outpatients (17 men and 24 women; age, 37 +/- 10 yr), in remission (CD Activity Index < 150) for > 3 months, and 25 age-matched healthy controls (10 men and 15 women; age, 37 +/- 13 yr) were evaluated.
  • CONCLUSIONS: CD patients in clinical remission have decreased muscle function that may affect their quality of life.
  • [MeSH-minor] Adult. Case-Control Studies. Female. Hand Strength. Humans. Male. Middle Aged. Severity of Illness Index. Steroids / therapeutic use

  • Genetic Alliance. consumer health - Crohn Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15735436.001).
  • [ISSN] 1078-0998
  • [Journal-full-title] Inflammatory bowel diseases
  • [ISO-abbreviation] Inflamm. Bowel Dis.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Steroids
  •  go-up   go-down


58. Jäger M, Messer T, Laux G, Pfeiffer H, Naber D, Schmidt LG, Gaebel W, Klosterkötter J, Heuser I, Maier W, Lemke MR, Rüther E, Buchkremer G, Gastpar M, Riedel M, Bottlender R, Strauss A, Möller HJ: Standardized remission criteria in schizophrenia: descriptive validity and comparability with previously used outcome measures. Pharmacopsychiatry; 2008 Sep;41(5):190-5
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Standardized remission criteria in schizophrenia: descriptive validity and comparability with previously used outcome measures.
  • INTRODUCTION: Standardized consensus criteria for remission in schizophrenia were recently proposed.
  • METHODS: The symptom-severity component of the proposed remission criteria was applied to 288 inpatients who fulfilled the ICD-10 criteria for schizophrenia.
  • RESULTS: When patients with symptom remission at discharge from hospitalization (n=158, 54.9%) were compared to those without symptom remission, significant differences were found with respect to the global functioning (GAF) and all observed psychopathological symptom dimensions.
  • DISCUSSION: The results indicate a high descriptive validity of the symptom-severity component of the proposed remission definition.
  • [MeSH-minor] Adolescent. Adult. Aged. Female. Follow-Up Studies. Humans. Male. Middle Aged. Psychiatric Status Rating Scales / statistics & numerical data. Randomized Controlled Trials as Topic. Remission Induction. Reproducibility of Results. Retrospective Studies. Severity of Illness Index

  • Genetic Alliance. consumer health - Schizophrenia.
  • MedlinePlus Health Information. consumer health - Schizophrenia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18763221.001).
  • [ISSN] 0176-3679
  • [Journal-full-title] Pharmacopsychiatry
  • [ISO-abbreviation] Pharmacopsychiatry
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  •  go-up   go-down


59. Willemze R, Labar B: Post-remission treatment for adult patients with acute lymphoblastic leukemia in first remission: is there a role for autologous stem cell transplantation? Semin Hematol; 2007 Oct;44(4):267-73
Genetic Alliance. consumer health - Transplantation.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Post-remission treatment for adult patients with acute lymphoblastic leukemia in first remission: is there a role for autologous stem cell transplantation?
  • Allogeneic stem cell transplantation (alloSCT) or autologous SCT (autoSCT) and intensive consolidation/intensification courses plus maintenance chemotherapy for 1 to 2 years are currently the major options for post-remission treatment of adult patients with acute lymphoblastic leukemia (ALL) in first remission.
  • Herein, we try to dissect data from these randomized trials to evaluate the role of autoSCT in patients with ALL in complete remission.
  • [MeSH-major] Precursor Cell Lymphoblastic Leukemia-Lymphoma / radiotherapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / surgery. Stem Cell Transplantation / methods. Transplantation, Autologous
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Combined Modality Therapy / mortality. Disease-Free Survival. Evidence-Based Medicine. Humans. Randomized Controlled Trials as Topic / methods. Remission Induction. Survival Rate. Transplantation Conditioning / methods. Transplantation, Homologous. Treatment Outcome. Whole-Body Irradiation

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17961726.001).
  • [ISSN] 0037-1963
  • [Journal-full-title] Seminars in hematology
  • [ISO-abbreviation] Semin. Hematol.
  • [Language] eng
  • [Publication-type] Comparative Study; Evaluation Studies; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 76
  •  go-up   go-down


60. Weil RJ, Vortmeyer AO, Nieman LK, Devroom HL, Wanebo J, Oldfield EH: Surgical remission of pituitary adenomas confined to the neurohypophysis in Cushing's disease. J Clin Endocrinol Metab; 2006 Jul;91(7):2656-64
Hazardous Substances Data Bank. Corticotropin .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgical remission of pituitary adenomas confined to the neurohypophysis in Cushing's disease.
  • At follow-up of 71.9 +/- 34.2 months (range, 30-138 months), all patients are in remission of CD.
  • Adult patients have had significant improvement in weight and body mass indices, with restoration of normal menses in all women.
  • In the four pediatric patients, height, weight, and body mass indices have been restored toward normal by surgical remission of CD.
  • In cases of CD in which an adenoma is not identified in the adenohypophysis and in patients with persistent hypercortisolism after complete or partial excision of the anterior lobe, tumor within the neurohypophysis should be considered; selective adenomectomy of a neurohypophyseal, ACTH-secreting tumor can produce long-term remission.
  • [MeSH-minor] Adolescent. Adrenocorticotropic Hormone / analysis. Adult. Aged. Body Height. Body Mass Index. Body Weight. Child. Cushing Syndrome / surgery. Female. Humans. Hypophysectomy / methods. Immunohistochemistry. Male. Menstrual Cycle. Middle Aged. Remission Induction / methods. Reoperation

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16636117.001).
  • [ISSN] 0021-972X
  • [Journal-full-title] The Journal of clinical endocrinology and metabolism
  • [ISO-abbreviation] J. Clin. Endocrinol. Metab.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 9002-60-2 / Adrenocorticotropic Hormone
  •  go-up   go-down


61. Horstmann S, Lucae S, Menke A, Hennings JM, Ising M, Roeske D, Müller-Myhsok B, Holsboer F, Binder EB: Polymorphisms in GRIK4, HTR2A, and FKBP5 show interactive effects in predicting remission to antidepressant treatment. Neuropsychopharmacology; 2010 Feb;35(3):727-40
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Polymorphisms in GRIK4, HTR2A, and FKBP5 show interactive effects in predicting remission to antidepressant treatment.
  • Response and remission of depressive symptoms after 5 weeks of antidepressant treatment were tested against 82 GRIK4 and 37 HTR2A SNPs.
  • The GRIK4 SNP (rs12800734, genotypic, p=0.0019, p(corrected)=0.12) and the HTR2A SNP (rs17288723, genotypic, p=0.0011, p(corrected)=0.02), which showed the strongest association with remission in our sample, had not been reported previously.
  • This three SNP model explained 13.1% of the variance for remission after 5 weeks (p=0.00051 for the model).
  • [MeSH-minor] Adult. Female. Genetic Markers / genetics. Humans. Male. Middle Aged. Predictive Value of Tests. Remission Induction. Treatment Outcome. Young Adult

  • MedlinePlus Health Information. consumer health - Antidepressants.
  • COS Scholar Universe. author profiles.
  • Pharmacogenomics Knowledge Base. meta-databases - Pharmacogenomic Annotation 827859151 for PMID:19924111 [PharmGKB] .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • SciCrunch. Clinical Genomic Database: Data: Gene Annotation .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Psychiatry. 2006 Jan;163(1):28-40 [16390886.001]
  • [Cites] Pharmacogenomics J. 2006 Jan-Feb;6(1):27-33 [16302021.001]
  • [Cites] Biol Psychiatry. 2000 Feb 15;47(4):305-13 [10686265.001]
  • [Cites] Biol Psychiatry. 2000 Apr 1;47(7):586-93 [10745050.001]
  • [Cites] Arch Gen Psychiatry. 2000 Sep;57(9):850-8 [10986548.001]
  • [Cites] Neuropsychopharmacology. 2000 Nov;23(5):477-501 [11027914.001]
  • [Cites] Neuron. 2000 Nov;28(2):335-41 [11144343.001]
  • [Cites] Neurosci Lett. 2001 May 4;303(2):119-22 [11311507.001]
  • [Cites] FEBS Lett. 2001 Apr 20;495(1-2):1-6 [11322937.001]
  • [Cites] J Neurosci. 2001 May 15;21(10):3572-9 [11331386.001]
  • [Cites] Int J Neuropsychopharmacol. 2002 Mar;5(1):27-35 [12057029.001]
  • [Cites] Science. 2002 Jun 21;296(5576):2225-9 [12029063.001]
  • [Cites] Neuropsychopharmacology. 2002 Sep;27(3):470-8 [12225704.001]
  • [Cites] J Clin Psychopharmacol. 2003 Apr;23(2):155-68 [12640217.001]
  • [Cites] Vitam Horm. 2003;66:189-255 [12852256.001]
  • [Cites] Am J Psychiatry. 2003 Sep;160(9):1554-65 [12944327.001]
  • [Cites] Neuropsychopharmacology. 2003 Dec;28(12):2169-78 [12931142.001]
  • [Cites] NMR Biomed. 2003 Oct-Nov;16(6-7):339-57 [14679499.001]
  • [Cites] Am J Psychiatry. 2004 Jan;161(1):171-4 [14702270.001]
  • [Cites] Biol Psychiatry. 2004 Feb 1;55(3):217-24 [14744461.001]
  • [Cites] Biol Psychiatry. 2004 Feb 1;55(3):225-33 [14744462.001]
  • [Cites] Am J Psychiatry. 2004 May;161(5):780-96 [15121641.001]
  • [Cites] Mol Psychiatry. 2004 Sep;9(9):879-89 [15052272.001]
  • [Cites] Science. 1980 Oct 3;210(4465):88-90 [6251550.001]
  • [Cites] J Pharmacol Exp Ther. 1982 May;221(2):303-8 [7077527.001]
  • [Cites] J Affect Disord. 1987 Jul-Aug;13(1):67-74 [2959702.001]
  • [Cites] Brain Res. 1989 Aug 14;494(2):315-24 [2570624.001]
  • [Cites] Biol Psychiatry. 1990 Mar 1;27(5):489-96 [2310804.001]
  • [Cites] Brain Res. 1990 Sep 17;527(2):198-203 [1701336.001]
  • [Cites] Psychopharmacology (Berl). 1992;108(1-2):27-32 [1384079.001]
  • [Cites] Endocrinology. 1993 Jul;133(1):312-20 [8391426.001]
  • [Cites] Biol Psychiatry. 2006 Mar 15;59(6):493-501 [16199008.001]
  • [Cites] Ann Med. 2006;38(2):82-94 [16581694.001]
  • [Cites] Biol Psychiatry. 2006 Apr 15;59(8):681-8 [16580345.001]
  • [Cites] Am J Hum Genet. 2006 May;78(5):804-14 [16642436.001]
  • [Cites] Science. 2006 Jul 28;313(5786):536-40 [16873667.001]
  • [Cites] Hum Mol Genet. 2006 Aug 15;15(16):2438-45 [16822851.001]
  • [Cites] Neuropsychobiology. 2006;53(4):186-95 [16874005.001]
  • [Cites] Cell Tissue Res. 2006 Nov;326(2):457-82 [16847640.001]
  • [Cites] Biol Psychiatry. 2007 Jan 15;61(2):162-6 [16735030.001]
  • [Cites] Biochim Biophys Acta. 2007 Mar;1770(3):489-94 [17113714.001]
  • [Cites] Mol Psychiatry. 2007 Mar;12(3):247-57 [17146470.001]
  • [Cites] Biol Psychiatry. 2007 Jul 1;62(1):47-54 [17123470.001]
  • [Cites] Am J Psychiatry. 2007 Aug;164(8):1181-8 [17671280.001]
  • [Cites] Biol Psychiatry. 2007 Dec 1;62(11):1310-6 [17574216.001]
  • [Cites] J Neurochem. 2007 Dec;103(6):2121-35 [18070252.001]
  • [Cites] Pharmacogenomics J. 2008 Feb;8(1):4-15 [17549068.001]
  • [Cites] Neuron. 2008 Jan 24;57(2):203-9 [18215618.001]
  • [Cites] Pharmacogenomics J. 2008 Apr;8(2):90-100 [17684474.001]
  • [Cites] PLoS One. 2008;3(4):e1872 [18382661.001]
  • [Cites] Am J Med Genet C Semin Med Genet. 2008 May 15;148C(2):89-98 [18412102.001]
  • [Cites] Nat Rev Drug Discov. 2008 May;7(5):426-37 [18425072.001]
  • [Cites] Biol Psychiatry. 2008 Jun 15;63(12):1103-10 [18191112.001]
  • [Cites] Pharmacogenomics. 2008 Jul;9(7):841-6 [18597649.001]
  • [Cites] Nat Rev Neurosci. 2008 Aug;9(8):638-46 [18628772.001]
  • [Cites] Eur J Neurosci. 2008 Jul;28(2):389-98 [18702710.001]
  • [Cites] Psychoneuroendocrinology. 2009 Jan;34(1):99-109 [18829172.001]
  • [Cites] J Psychiatr Res. 2009 Jan;43(3):215-29 [18586274.001]
  • [Cites] Depress Anxiety. 2009;26(1):83-97 [18833573.001]
  • [Cites] Biol Psychiatry. 2009 May 1;65(9):785-91 [19095219.001]
  • [Cites] Mol Psychiatry. 2009 Jun;14(6):614-20 [18268501.001]
  • [Cites] Pharmacol Ther. 2009 Oct;124(1):57-73 [19563827.001]
  • [Cites] Arch Gen Psychiatry. 2009 Sep;66(9):966-75 [19736353.001]
  • [Cites] Mol Psychiatry. 2010 May;15(5):473-500 [18982004.001]
  • [Cites] Am J Psychiatry. 1993 Nov;150(11):1731-3 [8214185.001]
  • [Cites] Biol Psychiatry. 1994 Oct 1;36(7):467-71 [7811843.001]
  • [Cites] J Psychiatr Res. 1994 Jul-Aug;28(4):341-56 [7877114.001]
  • [Cites] Biol Psychiatry. 1995 Mar 15;37(6):383-93 [7772647.001]
  • [Cites] Psychiatr Clin North Am. 1996 Jun;19(2):179-200 [8827185.001]
  • [Cites] Psychoneuroendocrinology. 1997 Oct;22(7):477-91 [9373882.001]
  • [Cites] J Psychiatr Res. 1998 Sep-Oct;32(5):255-9 [9789202.001]
  • [Cites] Neuropharmacology. 1999 Aug;38(8):1083-152 [10462127.001]
  • [Cites] Psychopharmacologia. 1961 Dec 19;2:381-407 [13861628.001]
  • [Cites] Nat Genet. 2004 Dec;36(12):1319-25 [15565110.001]
  • [Cites] Bioinformatics. 2005 Jan 15;21(2):263-5 [15297300.001]
  • [Cites] Psychol Med. 2004 Oct;34(7):1299-308 [15697056.001]
  • [Cites] Am J Hum Genet. 2005 May;76(5):887-93 [15789306.001]
  • [Cites] Prog Neuropsychopharmacol Biol Psychiatry. 2005 Jul;29(6):1085-93 [15950349.001]
  • [Cites] Neuropsychobiology. 2005;52(3):155-62 [16127283.001]
  • [Cites] Nat Genet. 2005 Nov;37(11):1217-23 [16244653.001]
  • [Cites] Am J Psychiatry. 2005 Dec;162(12):2379-81 [16330605.001]
  • (PMID = 19924111.001).
  • [ISSN] 1740-634X
  • [Journal-full-title] Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology
  • [ISO-abbreviation] Neuropsychopharmacology
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Multicenter Study
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antidepressive Agents; 0 / GRIK4 protein, human; 0 / Genetic Markers; 0 / Receptor, Serotonin, 5-HT2A; 0 / Receptors, Kainic Acid; EC 5.2.1.- / Tacrolimus Binding Proteins; EC 5.2.1.8 / tacrolimus binding protein 5
  • [Other-IDs] NLM/ PMC3055621
  •  go-up   go-down


62. Helldin L, Kane JM, Karilampi U, Norlander T, Archer T: Remission and cognitive ability in a cohort of patients with schizophrenia. J Psychiatr Res; 2006 Dec;40(8):738-45
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Remission and cognitive ability in a cohort of patients with schizophrenia.
  • INTRODUCTION: Patients with schizophrenia were studied regarding their ability of achieving symptomatic remission.
  • It was found that only approximately one-third of the patients fulfilled the criteria for remission.
  • The importance of cognitive performance was studied to decide whether cognitive ability is a contributing factor for achieving remission.
  • MATERIALS AND METHODS: A homogeneous cohort of 211 patients, of whom 76 patients attained remission (36%), and 135 patients (64%) failed to, was studied.
  • Remission was decided by the use of eight items from the PANSS in which none of these items should have a score above three points.
  • RESULTS: Marked differences were exhibited in the cognitive abilities in all domains of patients who had attained remission in comparison with those who had not.
  • DISCUSSION: This study highlights the importance of cognitive performance as one possible predictor of remission.
  • Patients without remission had lower cognitive ability and may have more difficulty in benefiting from, or complying with their treatment.
  • As a consequence, various forms of supportive treatment might increase the likelihood of remission.
  • [MeSH-minor] Adult. Cohort Studies. Female. Humans. Male. Neuropsychological Tests. Remission Induction. Severity of Illness Index. Surveys and Questionnaires

  • Genetic Alliance. consumer health - Schizophrenia.
  • MedlinePlus Health Information. consumer health - Schizophrenia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16963087.001).
  • [ISSN] 0022-3956
  • [Journal-full-title] Journal of psychiatric research
  • [ISO-abbreviation] J Psychiatr Res
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


63. Gaussmann AB, Imhoff D, Lambrecht E, Menzel C, Mose S: Spontaneous remission of metastases of cancer of the uterine cervix. Onkologie; 2006 Apr;29(4):159-61
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Spontaneous remission of metastases of cancer of the uterine cervix.
  • BACKGROUND: Spontaneous remission (SR) is the complete or incomplete disappearance of a disease or cancer despite no or inadequate treatment.
  • In all other metastases, spontaneous remission occurred.
  • [MeSH-minor] Adult. Female. Humans


64. Torelli GF, Guarini A, Maggio R, Alfieri C, Vitale A, Foà R: Expansion of natural killer cells with lytic activity against autologous blasts from adult and pediatric acute lymphoid leukemia patients in complete hematologic remission. Haematologica; 2005 Jun;90(6):785-92
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expansion of natural killer cells with lytic activity against autologous blasts from adult and pediatric acute lymphoid leukemia patients in complete hematologic remission.
  • The anti-leukemic activity of NK cells against acute myeloid leukemia (AML) blasts has been described, but very few data are available for acute lymphoid leukemia (ALL).
  • The present study was designed to investigate whether: (i) NK effectors could be expanded from adult and pediatric ALL patients in complete remission;.
  • (v) any differences in cytotoxic activity could be found between expanded effectors from adult and pediatric patients.
  • No differences in expansion and cytotoxic activity were found between pediatric and adult patients.
  • INTERPRETATION AND CONCLUSIONS: These findings document for the first time the possibility of expanding ex vivo cytotoxic effectors with autologous killing capacity from ALL patients in remission, and suggest a new potential immunotherapeutic strategy for the management of early disease recurrence or of residual disease.
  • [MeSH-major] Immunotherapy / methods. Killer Cells, Natural / cytology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / metabolism. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy
  • [MeSH-minor] Adult. Child. Coculture Techniques. Cytokines / metabolism. Flow Cytometry. Humans. Interleukin-15 / metabolism. Interleukin-2 / metabolism. Receptors, IgG / metabolism. Remission Induction. Signal Transduction

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15951291.001).
  • [ISSN] 1592-8721
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Cytokines; 0 / Interleukin-15; 0 / Interleukin-2; 0 / Receptors, IgG
  •  go-up   go-down


65. Ketter TA, Agid O, Kapur S, Loebel A, Siu CO, Romano SJ: Rapid antipsychotic response with ziprasidone predicts subsequent acute manic/mixed episode remission. J Psychiatr Res; 2010 Jan;44(1):8-14
Hazardous Substances Data Bank. Ziprasidone .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rapid antipsychotic response with ziprasidone predicts subsequent acute manic/mixed episode remission.
  • OBJECTIVE: To assess rapid antipsychotic efficacy with oral ziprasidone monotherapy in bipolar acute manic/mixed episodes with psychotic features, and predictive value of rapid antipsychotic response for subsequent acute manic/mixed episode remission.
  • Rapid antipsychotic response (>or=50% decrease in SADS-C psychosis score by Day 4) and acute manic episode response and remission (endpoint >or=50% MRS decrease, and a MRS score <or=12, respectively) were analyzed.
  • Rapid antipsychotic response predicted subsequent acute manic episode remission independent of ziprasidone or placebo treatment received (p<0.001, ROC AUC=0.71) with significant improvement in accuracy of MRS remission prediction when compared to models using early changes in MRS score alone (p=0.01).
  • CONCLUSIONS: The predictive value of rapid (Day 4) improvement in psychotic symptoms for subsequent (Day 21) remission of acute manic/mixed symptoms may facilitate enhanced therapeutics, in view of the current practice of brief hospitalization for patients with acute manic/mixed episodes with psychotic features.
  • [MeSH-minor] Adult. Area Under Curve. Dose-Response Relationship, Drug. Double-Blind Method. Female. Humans. Male. Middle Aged. Predictive Value of Tests. Psychiatric Status Rating Scales. ROC Curve. Secondary Prevention. Time Factors. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Bipolar Disorder.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19699488.001).
  • [ISSN] 1879-1379
  • [Journal-full-title] Journal of psychiatric research
  • [ISO-abbreviation] J Psychiatr Res
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Randomized Controlled Trial
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antipsychotic Agents; 0 / Piperazines; 0 / Thiazoles; 6UKA5VEJ6X / ziprasidone
  •  go-up   go-down


66. Mahadevan U, Kane S, Sandborn WJ, Cohen RD, Hanson K, Terdiman JP, Binion DG: Intentional infliximab use during pregnancy for induction or maintenance of remission in Crohn's disease. Aliment Pharmacol Ther; 2005 Mar 15;21(6):733-8
Hazardous Substances Data Bank. Infliximab .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intentional infliximab use during pregnancy for induction or maintenance of remission in Crohn's disease.
  • These data, combined with other studies of inadvertent use of infliximab during pregnancy, suggest that the benefits of infliximab in achieving response and maintaining remission in mothers with Crohn's disease may outweigh the risk to the foetus of exposure to the drug.
  • [MeSH-minor] Abnormalities, Drug-Induced / etiology. Adult. Female. Fetal Growth Retardation / chemically induced. Gestational Age. Humans. Infant, Newborn. Infant, Small for Gestational Age. Infliximab. Middle Aged. Pregnancy. Retrospective Studies


67. Petronijević ND, Radonjić NV, Ivković MD, Marinković D, Piperski VD, Duricić BM, Paunović VR: Plasma homocysteine levels in young male patients in the exacerbation and remission phase of schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry; 2008 Dec 12;32(8):1921-6
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Plasma homocysteine levels in young male patients in the exacerbation and remission phase of schizophrenia.
  • Plasma Hcy concentrations were measured in male chronic schizophrenic patients with a predominantly positive (SCH (+)) or predominantly negative (SCH (-)) syndrome in schizophrenia immediately upon admission to the hospital (exacerbation phase) and one month later (remission phase).
  • All patients exhibited decreased plasma Hcy levels in the remission phase of the illness, with a mean decrease of 2.68+/-1.57 micromol/L.
  • Folate and B12 levels did not differ in the exacerbation and remission phases of the illness.
  • The significant decrease of plasma Hcy levels, without changes in folate and vitamin B12 concentrations in the remission phase of schizophrenia, could indicate an influence of a pathogenetic process involved in schizophrenia on Hcy metabolism.
  • [MeSH-minor] Adult. Analysis of Variance. Antipsychotic Agents / therapeutic use. Female. Humans. Male. Middle Aged. Statistics as Topic. Young Adult

  • Genetic Alliance. consumer health - Schizophrenia.
  • MedlinePlus Health Information. consumer health - Schizophrenia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18824063.001).
  • [ISSN] 0278-5846
  • [Journal-full-title] Progress in neuro-psychopharmacology & biological psychiatry
  • [ISO-abbreviation] Prog. Neuropsychopharmacol. Biol. Psychiatry
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antipsychotic Agents; 0LVT1QZ0BA / Homocysteine
  •  go-up   go-down


68. Calvet X, Gallardo O, Coronas R, Casellas F, Montserrat A, Torrejón A, Vergara M, Campo R, Brullet E: Remission on thiopurinic immunomodulators normalizes quality of life and psychological status in patients with Crohn's disease. Inflamm Bowel Dis; 2006 Aug;12(8):692-6
Hazardous Substances Data Bank. MERCAPTOPURINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Remission on thiopurinic immunomodulators normalizes quality of life and psychological status in patients with Crohn's disease.
  • BACKGROUND: Thiopurinic immunomodulators are effective for maintaining symptom remission in Crohn's disease.
  • The present study aimed to determine whether remission induced by thiopurinic immunomodulators returns levels of quality of life and psychological well-being to normal.
  • Cases were 33 patients with Crohn's disease treated with azathioprine or 6-mercaptopurine and in stable remission for at least 6 months.
  • CONCLUSIONS: Thiopurinic immunomodulator-induced remission restores normal levels of quality of life and psychological well-being in Crohn's disease patients.
  • [MeSH-minor] Adult. Anxiety / diagnosis. Anxiety / etiology. Case-Control Studies. Depression / diagnosis. Depression / etiology. Female. Humans. Male. Remission Induction

  • Genetic Alliance. consumer health - Crohn Disease.
  • MedlinePlus Health Information. consumer health - Crohn's Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16917223.001).
  • [ISSN] 1078-0998
  • [Journal-full-title] Inflammatory bowel diseases
  • [ISO-abbreviation] Inflamm. Bowel Dis.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Immunosuppressive Agents; E7WED276I5 / 6-Mercaptopurine
  •  go-up   go-down


69. Huda MS, Athauda NB, Teh MM, Carroll PV, Powrie JK: Factors determining the remission of microprolactinomas after dopamine agonist withdrawal. Clin Endocrinol (Oxf); 2010 Apr;72(4):507-11

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Factors determining the remission of microprolactinomas after dopamine agonist withdrawal.
  • BACKGROUND: Withdrawal of dopamine agonist (DA) therapy in the management of microprolactinoma is common practice, but it is unclear which patients are likely to attain long-term remission.
  • OBJECTIVE: To identify predictive factors for long-term remission.
  • Normalization of MRI prior to DA withdrawal (P = 0.0006) and longer duration of DA treatment (P = 0.032) were significant predictors of remission.
  • Age, pre-treatment prolactin, nadir prolactin, previous failure of DA withdrawal, pregnancy, dose and type of DA were not significant predictors of remission.
  • The nine patients who were in remission at 12 months were then followed up for 58.0 +/- 5.8 months; all remained in remission.
  • CONCLUSIONS: As many as 22.5% of subjects with microprolactinoma remained normoprolactinaemic 12 months after DA withdrawal and these subjects stayed in remission for up to 5 years.
  • [MeSH-minor] Adult. Cohort Studies. Female. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Prospective Studies. Recurrence. Withholding Treatment

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19549247.001).
  • [ISSN] 1365-2265
  • [Journal-full-title] Clinical endocrinology
  • [ISO-abbreviation] Clin. Endocrinol. (Oxf)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Dopamine Agonists; 9002-62-4 / Prolactin
  •  go-up   go-down


70. Emsley R, Rabinowitz J, Medori R, Early Psychosis Global Working Group: Remission in early psychosis: Rates, predictors, and clinical and functional outcome correlates. Schizophr Res; 2007 Jan;89(1-3):129-39
Hazardous Substances Data Bank. HALOPERIDOL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Remission in early psychosis: Rates, predictors, and clinical and functional outcome correlates.
  • BACKGROUND: Recently, the "Remission in Schizophrenia Working Group" proposed remission criteria consisting of a reduction to mild levels on key symptoms for at least 6 months.
  • AIMS: This study applied these remission criteria to a large first-episode psychosis sample in order to (1) determine the rates of remission;.
  • (2) explore predictors of remission; and (3) test the external validity of these criteria.
  • RESULTS: At some time point in the study 323 (70%) of the 462 subjects had a reduction to mild levels on the key symptoms as measured by the PANSS although only 109 (23.6%) maintained this level for at least 6 months thereby meeting remission criteria.
  • The two strongest predictors of remission were shorter duration of untreated psychosis (p=0.01) and treatment response at 6 weeks (p=0.001).
  • Compared to non-remitted patients, those in remission experienced greater improvement on all PANSS subscales (p<.0001), CGI-S (p<.0001), better quality of life (p=0.006), fewer relapses (p<.0001), displayed a more favorable attitude towards their medication (p=.002), had lower EPS levels according to the ESRS (p=<.0001) and received lower doses of antipsychotic medication (p=0.003).
  • The remission and non-remission groups did not differ significantly regarding composite cognitive scores, suicidality and body mass index.
  • CONCLUSIONS: The results suggest that the remission criteria, although based solely on core symptom improvement, can effectively identify patients who have a more favorable overall outcome.
  • [MeSH-minor] Adolescent. Adult. Dose-Response Relationship, Drug. Double-Blind Method. Dyskinesia, Drug-Induced / diagnosis. Female. Follow-Up Studies. Humans. Long-Term Care. Male. Motivation. Quality of Life / psychology. Secondary Prevention. Sick Role. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Schizophrenia.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. RISPERIDONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17095194.001).
  • [ISSN] 0920-9964
  • [Journal-full-title] Schizophrenia research
  • [ISO-abbreviation] Schizophr. Res.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antipsychotic Agents; J6292F8L3D / Haloperidol; L6UH7ZF8HC / Risperidone
  •  go-up   go-down


71. Cornelissen JJ, van der Holt B, Verhoef GE, van't Veer MB, van Oers MH, Schouten HC, Ossenkoppele G, Sonneveld P, Maertens J, van Marwijk Kooy M, Schaafsma MR, Wijermans PW, Biesma DH, Wittebol S, Voogt PJ, Baars JW, Zachée P, Verdonck LF, Löwenberg B, Dekker AW, Dutch-Belgian HOVON Cooperative Group: Myeloablative allogeneic versus autologous stem cell transplantation in adult patients with acute lymphoblastic leukemia in first remission: a prospective sibling donor versus no-donor comparison. Blood; 2009 Feb 5;113(6):1375-82
Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Myeloablative allogeneic versus autologous stem cell transplantation in adult patients with acute lymphoblastic leukemia in first remission: a prospective sibling donor versus no-donor comparison.
  • While commonly accepted in poor-risk acute lymphoblastic leukemia (ALL), the role of allogeneic hematopoietic stem cell transplantation (allo-SCT) is still disputed in adult patients with standard-risk ALL.
  • We evaluated outcome of patients with ALL in first complete remission (CR1), according to a sibling donor versus no-donor comparison.
  • [MeSH-major] Hematopoietic Stem Cell Transplantation. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy. Transplantation, Autologous / methods. Transplantation, Homologous / methods
  • [MeSH-minor] Adolescent. Adult. Antineoplastic Agents / therapeutic use. Disease-Free Survival. Female. Humans. Living Donors. Male. Middle Aged. Neoplasm Recurrence, Local / diagnosis. Neoplasm Recurrence, Local / therapy. Prospective Studies. Remission Induction. Risk Factors. Siblings. Transplantation Conditioning. Treatment Outcome. Young Adult

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18988865.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Investigator] Cornelissen JJ; van der Holt B; Verhoef GE; van't Veer MB; van Oers MH; Schouten HC; Ossenkoppele G; Sonneveld P; Maertens J; van Marwijk Kooy M; Schaafsma MR; Wijermans PW; Biesma DH; Wittebol S; Voogt PJ; Baars JW; Zachée P; Verdonck LF; Löwenberg B; Dekker AW
  •  go-up   go-down


72. Reinfjell T, Lofstad GE, Nordahl HM, Vikan A, Diseth TH: Children in remission from acute lymphoblastic leukaemia: mental health, psychosocial adjustment and parental functioning. Eur J Cancer Care (Engl); 2009 Jul;18(4):364-70
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Children in remission from acute lymphoblastic leukaemia: mental health, psychosocial adjustment and parental functioning.
  • Children in remission from acute lymphoblastic leukaemia: mental health, psychosocial adjustment and parental functioningThe objective of this study is to assess the mental health and psychosocial adjustment of children in remission from acute lymphoblastic leukaemia (ALL), and parental functioning compared to healthy controls.
  • Children in remission from ALL showed on average significantly more problems regarding mental health and psychosocial adjustment, as reported by their parents, compared with healthy controls.
  • Adequate rehabilitation and follow-up programmes should be implemented for children in remission from ALL.
  • [MeSH-major] Adaptation, Psychological. Mental Disorders / epidemiology. Parents / psychology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / psychology
  • [MeSH-minor] Adolescent. Adult. Anxiety / epidemiology. Child. Cross-Sectional Studies. Depression / epidemiology. Female. Health Status. Humans. Male. Middle Aged. Norway. Remission Induction. Surveys and Questionnaires

  • MedlinePlus Health Information. consumer health - Child Mental Health.
  • MedlinePlus Health Information. consumer health - Mental Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19473372.001).
  • [ISSN] 1365-2354
  • [Journal-full-title] European journal of cancer care
  • [ISO-abbreviation] Eur J Cancer Care (Engl)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


73. Al Khabori M, Samiee S, Fung S, Xu W, Brandwein J, Patterson B, Brien W, Chang H: Adult precursor T-lymphoblastic leukemia/lymphoma with myeloid-associated antigen expression is associated with a lower complete remission rate following induction chemotherapy. Acta Haematol; 2008;120(1):5-10
Genetic Alliance. consumer health - Lymphoblastic lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adult precursor T-lymphoblastic leukemia/lymphoma with myeloid-associated antigen expression is associated with a lower complete remission rate following induction chemotherapy.
  • Prognostic studies of T-cell lymphoblastic leukemia/lymphoma (T-ALL) have been performed in small patient cohorts with conflicting results.
  • We systematically reviewed 67 adult T-ALL patients diagnosed and treated at our institute to identify clinical and pathologic prognostic factors.
  • Fifty-six of 64 patients (88%) achieved complete remission (CR).
  • Our study indicates that expression of myeloid-associated antigens is associated with a lower CR rate in adult T-ALL and may be considered in risk stratification for induction chemotherapy.
  • [MeSH-major] Antigens, Differentiation, Myelomonocytic / metabolism. Leukemia-Lymphoma, Adult T-Cell / drug therapy. Leukemia-Lymphoma, Adult T-Cell / immunology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Antigens, CD / metabolism. Antigens, CD13 / metabolism. Antigens, CD34 / metabolism. Antineoplastic Agents / therapeutic use. Antineoplastic Combined Chemotherapy Protocols. Disease-Free Survival. Female. Humans. Male. Middle Aged. Neprilysin / metabolism. Prognosis. Remission Induction. Sialic Acid Binding Ig-like Lectin 3. Survival Rate

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2008 S. Karger AG, Basel.
  • [CommentIn] Expert Rev Hematol. 2009 Feb;2(1):27-9 [21082991.001]
  • (PMID = 18635939.001).
  • [ISSN] 1421-9662
  • [Journal-full-title] Acta haematologica
  • [ISO-abbreviation] Acta Haematol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, CD34; 0 / Antigens, Differentiation, Myelomonocytic; 0 / Antineoplastic Agents; 0 / CD33 protein, human; 0 / Sialic Acid Binding Ig-like Lectin 3; EC 3.4.11.2 / Antigens, CD13; EC 3.4.24.11 / Neprilysin
  •  go-up   go-down


74. Shikata K, Haneda M, Koya D, Suzuki Y, Tomino Y, Yamada K, Maeda S, Kawakami N, Uzu T, Nishimura M, Sato C, Ogawa D, Makino H, DNETT-Japan Study Group: Diabetic Nephropathy Remission and Regression Team Trial in Japan (DNETT-Japan): Rationale and study design. Diabetes Res Clin Pract; 2010 Feb;87(2):228-32
MedlinePlus Health Information. consumer health - Diabetic Kidney Problems.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diabetic Nephropathy Remission and Regression Team Trial in Japan (DNETT-Japan): Rationale and study design.
  • Diabetic Nephropathy Remission and Regression Team Trial in Japan (DNETT-Japan) is an open, randomized controlled trial to evaluate the efficacy of renal protection of multifactorial intensive therapy in type 2 diabetes patients with overt proteinuria (urinary albumin-to-creatinine ratio > or =300 mg/g creatinine).
  • [MeSH-minor] Adult. Aged. Albuminuria. Blood Glucose / analysis. Blood Pressure. Creatinine / blood. Diet, Diabetic. Disease Progression. Female. Humans. Japan. Lipids / blood. Male. Middle Aged. Proteinuria. Remission, Spontaneous. Research Design. Young Adult

  • MedlinePlus Health Information. consumer health - Diabetes Type 2.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2009 Elsevier Ireland Ltd. All rights reserved.
  • (PMID = 19889469.001).
  • [ISSN] 1872-8227
  • [Journal-full-title] Diabetes research and clinical practice
  • [ISO-abbreviation] Diabetes Res. Clin. Pract.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Blood Glucose; 0 / Lipids; AYI8EX34EU / Creatinine
  •  go-up   go-down


75. Cantini F, Niccoli L, Nannini C, Cassarà E, Pasquetti P, Olivieri I, Salvarani C: Frequency and duration of clinical remission in patients with peripheral psoriatic arthritis requiring second-line drugs. Rheumatology (Oxford); 2008 Jun;47(6):872-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Frequency and duration of clinical remission in patients with peripheral psoriatic arthritis requiring second-line drugs.
  • OBJECTIVE: To evaluate the frequency and duration of clinical remission in patients with PsA.
  • Primary end point was to assess the frequency of remission in peripheral PsA compared with RA.
  • Secondary end points were to compare the duration of clinical remission during treatment and after therapy interruption, ACR 20, 50, 70 response rates and to detect any remission predictor at diagnosis.
  • From January 2003 to December 2005, therapy was suspended in PsA patients and controls if achieving remission.
  • RESULTS: One or more episodes of remission occurred in 57/236 (24.1%) PsA patients and in 20/268 (7.5%) controls (P < 0.001).
  • The mean duration of remission was of 13 +/- 9.4 months in PsA patients and 4 +/- 3.7 in controls (P > 0.001).
  • Remission episodes were more frequent in PsA patients treated with anti-TNF compared with those receiving traditional DMARDs (P > 0.001), with no differences regarding the duration.
  • After therapy interruption, the remission duration was 12 +/- 2.4 months in PsA and 3 +/- 1.5 in RA (P < 0.001).
  • No remission predictor at diagnosis resulted by multivariate analysis.
  • CONCLUSION: Remission is possible in up to 24% of patients with peripheral PsA.
  • Patients remain in remission for a long period after therapy interruption, thus suggesting an intermittent therapeutic strategy.
  • [MeSH-minor] Adult. Arthritis, Rheumatoid / drug therapy. Drug Administration Schedule. Epidemiologic Methods. Female. Humans. Male. Methotrexate / administration & dosage. Methotrexate / therapeutic use. Middle Aged. Remission Induction. Severity of Illness Index. Time Factors. Treatment Outcome. Tumor Necrosis Factor-alpha / antagonists & inhibitors

  • Genetic Alliance. consumer health - Arthritis.
  • Genetic Alliance. consumer health - Psoriatic Arthritis.
  • MedlinePlus Health Information. consumer health - Psoriatic Arthritis.
  • Hazardous Substances Data Bank. METHOTREXATE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18400836.001).
  • [ISSN] 1462-0332
  • [Journal-full-title] Rheumatology (Oxford, England)
  • [ISO-abbreviation] Rheumatology (Oxford)
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antirheumatic Agents; 0 / Tumor Necrosis Factor-alpha; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


76. Damjanovic SS, Neskovic AN, Petakov MS, Popovic V, Macut D, Vukojevic P, Joksimovic MM: Clinical indicators of biochemical remission in acromegaly: does incomplete disease control always mean therapeutic failure? Clin Endocrinol (Oxf); 2005 Apr;62(4):410-7
Genetic Alliance. consumer health - Acromegaly.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical indicators of biochemical remission in acromegaly: does incomplete disease control always mean therapeutic failure?
  • RESULTS: We found no difference in cardiac indices, insulin resistance, body composition and leptin levels between patients with complete biochemical remission and those with inadequately controlled disease (P > 0.05 for all) after TSS.
  • Independent predictors of biochemical remission, based on normal IGF-I levels only, were cardiac [P = 0.04, odds ratio (OR) 0.4; 95% confidence interval (CI) 0.2-0.9] and R(HOMA) index (P = 0.009, OR 0.6; 95% CI 0.4-0.8).
  • CONCLUSION: This study shows that cardiac indices, insulin resistance and body composition were not different between patients with complete biochemical remission and those with discordant GH and IGF-I levels.
  • [MeSH-minor] Absorptiometry, Photon. Adenoma / blood. Adenoma / complications. Adenoma / surgery. Adult. Aged. Area Under Curve. Biomarkers / blood. Blood Glucose / analysis. Body Composition. Echocardiography. Female. Growth Hormone / blood. Humans. Insulin / blood. Insulin-Like Growth Factor I / analysis. Leptin / blood. Lipids / blood. Logistic Models. Male. Middle Aged. Pituitary Neoplasms / blood. Pituitary Neoplasms / complications. Pituitary Neoplasms / surgery. Remission Induction. Treatment Failure

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15807870.001).
  • [ISSN] 0300-0664
  • [Journal-full-title] Clinical endocrinology
  • [ISO-abbreviation] Clin. Endocrinol. (Oxf)
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers; 0 / Blood Glucose; 0 / Insulin; 0 / Leptin; 0 / Lipids; 67763-96-6 / Insulin-Like Growth Factor I; 9002-72-6 / Growth Hormone
  •  go-up   go-down


77. Beckermann MJ: [Caring for women during perimenopause in the practice]. Ther Umsch; 2005 Dec;62(12):813-20
MedlinePlus Health Information. consumer health - Women's Health.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Placebo reduces the frequency of hot flashes by about 58% which confirms the very high rate of spontaneous remission of climacteric symptoms.
  • [MeSH-minor] Adult. Age Factors. Aged. Aged, 80 and over. Female. Humans. Middle Aged. Practice Guidelines as Topic. Practice Patterns, Physicians'

  • MedlinePlus Health Information. consumer health - Seniors' Health.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16405286.001).
  • [ISSN] 0040-5930
  • [Journal-full-title] Therapeutische Umschau. Revue thérapeutique
  • [ISO-abbreviation] Ther Umsch
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Estrogens; 0 / Progesterone Congeners
  • [Number-of-references] 20
  •  go-up   go-down


78. Ronchi CL, Varca V, Giavoli C, Epaminonda P, Beck-Peccoz P, Spada A, Arosio M: Long-term evaluation of postoperative acromegalic patients in remission with previous and newly proposed criteria. J Clin Endocrinol Metab; 2005 Mar;90(3):1377-82
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term evaluation of postoperative acromegalic patients in remission with previous and newly proposed criteria.
  • Criteria to define remission of acromegaly have changed over years.
  • This study reevaluated long-term disease activity of acromegalic patients, who were previously considered in remission, using these criteria.
  • [MeSH-minor] Adult. Aged. Female. Follow-Up Studies. Glucose Tolerance Test. Humans. Male. Middle Aged. Remission Induction. Time Factors. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15585548.001).
  • [ISSN] 0021-972X
  • [Journal-full-title] The Journal of clinical endocrinology and metabolism
  • [ISO-abbreviation] J. Clin. Endocrinol. Metab.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 12629-01-5 / Human Growth Hormone; 67763-96-6 / Insulin-Like Growth Factor I
  •  go-up   go-down


79. Larson RA: Allogeneic hematopoietic cell transplantation is not recommended for all adults with standard-risk acute lymphoblastic leukemia in first complete remission. Biol Blood Marrow Transplant; 2009 Jan;15(1 Suppl):11-6
Genetic Alliance. consumer health - Transplantation.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Allogeneic hematopoietic cell transplantation is not recommended for all adults with standard-risk acute lymphoblastic leukemia in first complete remission.
  • Acute lymphoblastic leukemia (ALL) is a heterogeneous disease, and outcomes vary by patient age, immunophenotype, and clinical, cytogenetic, and molecular features.
  • Available data indicate no clear consensus as to whether there is an advantage to allogeneic HCT over chemotherapy for adults with ALL with standard-risk features while in the first complete remission (CR1).
  • [MeSH-major] Hematopoietic Stem Cell Transplantation / methods. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy
  • [MeSH-minor] Adult. Age Factors. Humans. Remission Induction. Risk. Transplantation, Homologous. Treatment Outcome

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19147070.001).
  • [ISSN] 1523-6536
  • [Journal-full-title] Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
  • [ISO-abbreviation] Biol. Blood Marrow Transplant.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA-14599; United States / NCI NIH HHS / CA / CA-31946
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  •  go-up   go-down


80. Hamer HM, Jonkers DM, Vanhoutvin SA, Troost FJ, Rijkers G, de Bruïne A, Bast A, Venema K, Brummer RJ: Effect of butyrate enemas on inflammation and antioxidant status in the colonic mucosa of patients with ulcerative colitis in remission. Clin Nutr; 2010 Dec;29(6):738-44
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effect of butyrate enemas on inflammation and antioxidant status in the colonic mucosa of patients with ulcerative colitis in remission.
  • METHODS: Thirty-five patients with ulcerative colitis in clinical remission daily administered 60 ml rectal enemas containing 100mM sodium butyrate (n=17) or saline (n=18) during 20 days (NCT00696098).
  • CONCLUSION: Although UC patients in remission were characterized by low-grade oxidative stress and inflammation, rectal butyrate enemas showed only minor effects on inflammatory and oxidative stress parameters.
  • [MeSH-minor] Adult. Aged. Antioxidants / metabolism. Biopsy. Double-Blind Method. Enema. Female. Humans. Interleukin-10 / metabolism. Interleukin-12 / metabolism. Male. Middle Aged. Mucous Membrane

  • Genetic Alliance. consumer health - Ulcerative Colitis.
  • MedlinePlus Health Information. consumer health - Ulcerative Colitis.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Ltd and European Society for Clinical Nutrition and Metabolism. All rights reserved.
  • (PMID = 20471725.001).
  • [ISSN] 1532-1983
  • [Journal-full-title] Clinical nutrition (Edinburgh, Scotland)
  • [ISO-abbreviation] Clin Nutr
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antioxidants; 0 / Butyrates; 130068-27-8 / Interleukin-10; 187348-17-0 / Interleukin-12
  •  go-up   go-down


81. Strobel K, Schaefer NG, Renner C, Veit-Haibach P, Husarik D, Koma AY, Hany TF: Cost-effective therapy remission assessment in lymphoma patients using 2-[fluorine-18]fluoro-2-deoxy-D-glucose-positron emission tomography/computed tomography: is an end of treatment exam necessary in all patients? Ann Oncol; 2007 Apr;18(4):658-64
Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cost-effective therapy remission assessment in lymphoma patients using 2-[fluorine-18]fluoro-2-deoxy-D-glucose-positron emission tomography/computed tomography: is an end of treatment exam necessary in all patients?
  • RESULTS: In 31 (82%) HD patients, intPET demonstrated complete remission (CR) which was still present on endPET.
  • The remaining seven HD patients (18%) had partial remission (PR) on intPET.

  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17308330.001).
  • [ISSN] 0923-7534
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


82. Bassotti G, Villanacci V, Mazzocchi A, Castellani D, Giuliano V, Corsi S, Morelli A: Colonic propulsive and postprandial motor activity in patients with ulcerative colitis in remission. Eur J Gastroenterol Hepatol; 2006 May;18(5):507-10
MedlinePlus Health Information. consumer health - Ulcerative Colitis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Colonic propulsive and postprandial motor activity in patients with ulcerative colitis in remission.
  • AIMS: To assess the colonic high-amplitude and low-amplitude propulsive activity and the colonic motor response to eating in patients with ulcerative colitis in remission.
  • PATIENTS AND METHODS: Fourteen patients were recruited, all with the disease in remission as documented by clinical and endoscopic criteria.
  • CONCLUSIONS: Colonic propulsive activity in ulcerative colitis in remission is almost normal, even though the low-amplitude propagated activity tends to be similar to that observed in patients with the irritable bowel syndrome, thus possibly contributing to the persistence of abdominal symptoms in a subgroup of patients.
  • [MeSH-minor] Adult. Defecation / physiology. Female. Humans. Male. Manometry / methods. Middle Aged. Muscle Contraction / physiology

  • Genetic Alliance. consumer health - Ulcerative Colitis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16607145.001).
  • [ISSN] 0954-691X
  • [Journal-full-title] European journal of gastroenterology & hepatology
  • [ISO-abbreviation] Eur J Gastroenterol Hepatol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


83. Jeddi R, Mansouri R, Kacem K, Gouider E, Abid HB, Belhadjali Z, Meddeb B: Transfusion-related acute lung injury (TRALI) during remission induction course of acute myeloid leukemia: a possible role for all-transretinoic-acid (ATRA)? Pathol Biol (Paris); 2009 Sep;57(6):500-2
Hazardous Substances Data Bank. ALL-TRANS-RETINOIC ACID .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Transfusion-related acute lung injury (TRALI) during remission induction course of acute myeloid leukemia: a possible role for all-transretinoic-acid (ATRA)?
  • Transfusion-related acute lung injury (TRALI) is a clinical syndrome characterized by sudden onset of respiratory distress due to pulmonary edema during or following transfusion.
  • We report a case of TRALI occurring during remission induction course of acute myeloid leukemia in a 27-year-old woman who received All-transretinoic-acid (ATRA).
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Blood Transfusion / adverse effects. Leukemia, Myeloid, Acute / therapy. Leukocytosis / etiology. Tretinoin / therapeutic use
  • [MeSH-minor] Adult. Anemia / etiology. Female. Flow Cytometry. Humans. Remission Induction / methods. Respiratory Distress Syndrome, Adult / etiology


84. Sharma P, Makharia GK, Ahuja V, Dwivedi SN, Deepak KK: Autonomic dysfunctions in patients with inflammatory bowel disease in clinical remission. Dig Dis Sci; 2009 Apr;54(4):853-61
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Autonomic dysfunctions in patients with inflammatory bowel disease in clinical remission.
  • We therefore evaluated autonomic functions in patients with inflammatory bowel disease (IBD) in clinical remission.
  • [MeSH-minor] Adult. Case-Control Studies. Cross-Sectional Studies. Female. Humans. Male. Middle Aged. Nonlinear Dynamics. Time Factors. Young Adult

  • MedlinePlus Health Information. consumer health - Crohn's Disease.
  • MedlinePlus Health Information. consumer health - Ulcerative Colitis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18712478.001).
  • [ISSN] 1573-2568
  • [Journal-full-title] Digestive diseases and sciences
  • [ISO-abbreviation] Dig. Dis. Sci.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


85. De Groot K, Rasmussen N, Bacon PA, Tervaert JW, Feighery C, Gregorini G, Gross WL, Luqmani R, Jayne DR: Randomized trial of cyclophosphamide versus methotrexate for induction of remission in early systemic antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum; 2005 Aug;52(8):2461-9
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Randomized trial of cyclophosphamide versus methotrexate for induction of remission in early systemic antineutrophil cytoplasmic antibody-associated vasculitis.
  • The primary end point was the remission rate at 6 months (noninferiority testing).
  • At 6 months, the remission rate in patients treated with MTX (89.8%) was not inferior to that in patients treated with CYC (93.5%) (P = 0.041).
  • In the MTX group, remission was delayed among patients with more extensive disease (P = 0.04) or pulmonary involvement (P = 0.03).
  • Relapse rates at 18 months were 69.5% in the MTX group and 46.5% in the CYC group; the median time from remission to relapse was 13 months and 15 months, respectively (P = 0.023, log rank test).
  • The MTX regimen used in the present study was less effective for induction of remission in patients with extensive disease and pulmonary involvement and was associated with more relapses than the CYC regimen after termination of treatment.
  • [MeSH-minor] Adult. Aged. Anti-Inflammatory Agents / administration & dosage. Anti-Inflammatory Agents / therapeutic use. Dose-Response Relationship, Drug. Female. Humans. Male. Middle Aged. Prednisolone / administration & dosage. Prednisolone / therapeutic use. Recurrence. Remission Induction. Treatment Outcome

  • Genetic Alliance. consumer health - Vasculitis.
  • MedlinePlus Health Information. consumer health - Vasculitis.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Arthritis Rheum. 2005 Aug;52(8):2237-42 [16052540.001]
  • (PMID = 16052573.001).
  • [ISSN] 0004-3591
  • [Journal-full-title] Arthritis and rheumatism
  • [ISO-abbreviation] Arthritis Rheum.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents; 0 / Antibodies, Antineutrophil Cytoplasmic; 0 / Immunosuppressive Agents; 8N3DW7272P / Cyclophosphamide; 9PHQ9Y1OLM / Prednisolone; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


86. Tamam L, Tuğlu C, Karatas G, Ozcan S: Adult attention-deficit hyperactivity disorder in patients with bipolar I disorder in remission: preliminary study. Psychiatry Clin Neurosci; 2006 Aug;60(4):480-5
MedlinePlus Health Information. consumer health - Bipolar Disorder.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adult attention-deficit hyperactivity disorder in patients with bipolar I disorder in remission: preliminary study.
  • Prospective studies have demonstrated that at least half of children diagnosed as having ADHD continue to suffer the symptoms of this disorder in their adult life with significant impacts on their social status, achievement level and sense of well-being.
  • Forty-four BD-I patients followed up in psychiatric outpatient clinics in two university hospitals, were assessed for the presence of adult ADHD according to DSM-IV.
  • Of 44 patients with BD-I, only seven (15.9%) fulfilled criteria for a diagnosis of adult ADHD.
  • [MeSH-minor] Adult. Age of Onset. Female. Humans. Male. Middle Aged. Psychiatric Status Rating Scales. Socioeconomic Factors


87. Lindsay JR, Nansel T, Baid S, Gumowski J, Nieman LK: Long-term impaired quality of life in Cushing's syndrome despite initial improvement after surgical remission. J Clin Endocrinol Metab; 2006 Feb;91(2):447-53
MedlinePlus Health Information. consumer health - Cushing's Syndrome.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term impaired quality of life in Cushing's syndrome despite initial improvement after surgical remission.
  • METHODS: We used the short-form 36 survey to evaluate HRQL in 23 patients with Cushing's disease before and after transsphenoidal surgery (age, 42.7 +/- 12.0 yr; 19 women and four men) and in a cross-section of 343 CS patients (age, 48.2 +/- 14.1 yr; 265 women and 78 men) in remission for up to 25.8 yr after surgery (adrenal, 5%; ectopic, 6%).
  • In the cross-section in remission at follow-up, there was a small, but significant (P < 0.05), impairment of both PCS and MCS.
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Cohort Studies. Cross-Sectional Studies. Female. Humans. Male. Middle Aged. Prospective Studies. Quality of Life. Remission Induction. Surveys and Questionnaires

  • Genetic Alliance. consumer health - Cushing's Syndrome.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Nat Clin Pract Endocrinol Metab. 2006 Dec;2(12):666-7 [17143312.001]
  • (PMID = 16278266.001).
  • [ISSN] 0021-972X
  • [Journal-full-title] The Journal of clinical endocrinology and metabolism
  • [ISO-abbreviation] J. Clin. Endocrinol. Metab.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


88. Roberson JR, Spraker HL, Shelso J, Zhou Y, Inaba H, Metzger ML, Rubnitz JE, Ribeiro RC, Sandlund JT, Jeha S, Pui CH, Howard SC: Clinical consequences of hyperglycemia during remission induction therapy for pediatric acute lymphoblastic leukemia. Leukemia; 2009 Feb;23(2):245-50
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical consequences of hyperglycemia during remission induction therapy for pediatric acute lymphoblastic leukemia.
  • Hyperglycemia adversely affects outcome in adult patients with acute lymphoblastic leukemia (ALL), but its impact on children with this disease is unknown.
  • We evaluated the relationship between hyperglycemia during remission induction therapy and clinical outcomes among pediatric patients with ALL.
  • We reviewed the records of patients enrolled on four consecutive ALL protocols (Total Therapy protocols XIIIA, XIIIB, XIV and XV) at St Jude Children's Research Hospital from 1991 to 2007 and identified those who experienced hyperglycemia (glucose >or=200 mg per 100 ml) during remission induction.
  • Complete remission (CR) rates at the end of induction, event-free survival (EFS), overall survival (OS), cumulative incidence of relapse and occurrence of infections were compared between those who did and did not experience hyperglycemia.
  • Of 871 patients analyzed, 141 (16%) experienced hyperglycemia during remission induction.
  • Pediatric patients with or without hyperglycemia during remission induction for ALL have similar clinical outcome.

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • MedlinePlus Health Information. consumer health - Hyperglycemia.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Endocr Pract. 2004 Mar-Apr;10 Suppl 2:46-52 [15251640.001]
  • [Cites] Cancer. 2004 Oct 1;101(7):1677-84 [15378506.001]
  • [Cites] Blood. 2004 Nov 1;104(9):2690-6 [15251979.001]
  • [Cites] Cancer Chemother Rep. 1966 Mar;50(3):163-70 [5910392.001]
  • [Cites] Pediatrics. 1972 Apr;49(4):590-5 [4501679.001]
  • [Cites] Cancer Res. 1973 Jan;33(1):1-4 [4565907.001]
  • [Cites] Diabetes. 1974 Jan;23(1):9-15 [4809622.001]
  • [Cites] Diabetologia. 1978 Aug;15(2):113-6 [359390.001]
  • [Cites] Diabetes. 1980 Jul;29(7):528-31 [6991339.001]
  • [Cites] Metabolism. 1980 Dec;29(12):1262-6 [7005618.001]
  • [Cites] J Pediatr. 1981 Jul;99(1):46-50 [6454771.001]
  • [Cites] Horm Metab Res. 1984 Dec;16 Suppl 1:92-6 [6398268.001]
  • [Cites] J Trauma. 1990 Jul;30(7):830-2; discussion 832-3 [2380999.001]
  • [Cites] Indian J Cancer. 1993 Jun;30(2):72-6 [8225380.001]
  • [Cites] Zhonghua Yi Xue Za Zhi (Taipei). 1993 Jun;51(6):457-61 [8281494.001]
  • [Cites] FEMS Immunol Med Microbiol. 1993 Dec;7(4):315-20 [8136782.001]
  • [Cites] Arch Dis Child. 1996 Feb;74(2):101-7 [8660070.001]
  • [Cites] Horm Metab Res. 1996 Jun;28(6):267-70 [8811326.001]
  • [Cites] J Appl Physiol (1985). 1997 Nov;83(5):1566-74 [9375321.001]
  • [Cites] Blood. 1998 Jul 15;92(2):411-5 [9657739.001]
  • [Cites] J Pediatr. 2005 Jan;146(1):30-4 [15644818.001]
  • [Cites] Leukemia. 2005 Apr;19(4):537-44 [15690069.001]
  • [Cites] Pediatr Blood Cancer. 2005 Dec;45(7):960-3 [15700246.001]
  • [Cites] Acta Paediatr. 2006 Apr;95(4):486-93 [16720499.001]
  • [Cites] Pediatrics. 2006 Jul;118(1):173-9 [16818563.001]
  • [Cites] Pediatr Crit Care Med. 2006 Jul;7(4):351-5 [16738506.001]
  • [Cites] Pediatr Blood Cancer. 2008 Feb;50(2):259-63 [17635005.001]
  • [Cites] Pediatr Blood Cancer. 2008 Jun;50(6):1207-12 [18266226.001]
  • [Cites] J Clin Oncol. 2008 Apr 20;26(12):1932-9 [18421047.001]
  • [Cites] Helv Paediatr Acta. 1973 Oct;28(4):365-9 [4519479.001]
  • [Cites] J Clin Oncol. 2000 Feb;18(3):547-61 [10653870.001]
  • [Cites] J Trauma. 2001 Sep;51(3):540-4 [11535907.001]
  • [Cites] J Biol Chem. 2001 Oct 12;276(41):37747-53 [11489902.001]
  • [Cites] N Engl J Med. 2001 Nov 8;345(19):1359-67 [11794168.001]
  • [Cites] Pancreas. 2002 Jan;24(1):26-33 [11741179.001]
  • [Cites] J Clin Endocrinol Metab. 2002 Mar;87(3):978-82 [11889147.001]
  • [Cites] Childs Nerv Syst. 2002 Apr;18(3-4):129-36 [11981619.001]
  • [Cites] Blood Rev. 2002 Dec;16(4):225-43 [12350366.001]
  • [Cites] J Clin Oncol. 2003 Aug 15;21(16):3084-91 [12915598.001]
  • [Cites] JAMA. 2003 Oct 15;290(15):2041-7 [14559958.001]
  • [Cites] J Trauma. 2003 Dec;55(6):1035-8 [14676647.001]
  • [Cites] Cancer. 2004 Mar 15;100(6):1179-85 [15022284.001]
  • [Cites] Ann Hematol. 2004;83 Suppl 1:S124-6 [15124703.001]
  • [Cites] J Pediatr Surg. 2004 Jun;39(6):898-901; discussion 898-901 [15185221.001]
  • [Cites] Pediatr Crit Care Med. 2004 Jul;5(4):329-36 [15215001.001]
  • (PMID = 18923438.001).
  • [ISSN] 1476-5551
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] ENG
  • [Grant] United States / NIGMS NIH HHS / GM / U01 GM061393-09; United States / NCI NIH HHS / CA / CA-78224; United States / NCI NIH HHS / CA / R01 CA078224-09; United States / NIGMS NIH HHS / GM / U01 GM061393; United States / NCI NIH HHS / CA / CA-60419; United States / NCI NIH HHS / CA / R37 CA036401-21; United States / NCI NIH HHS / CA / R01 CA060419-13; United States / NCI NIH HHS / CA / R01 CA078224; United States / NCI NIH HHS / CA / R37 CA036401; None / None / / R01 CA051001-15; United States / NCI NIH HHS / CA / CA-36401; United States / NCI NIH HHS / CA / R01 CA060419; United States / NCI NIH HHS / CA / CA-51001; United States / NCI NIH HHS / CA / CA-21765; United States / NCI NIH HHS / CA / R01 CA051001-15; United States / NCI NIH HHS / CA / P30 CA021765; None / None / / R01 CA078224-09; None / None / / P30 CA021765-30; United States / NCI NIH HHS / CA / R01 CA051001; United States / NCI NIH HHS / CA / R01 CA036401; None / None / / R01 CA060419-13; United States / NCI NIH HHS / CA / P30 CA021765-30; United States / NIGMS NIH HHS / GM / GM-61393; United States / NCI NIH HHS / CA / U01 CA060419; United States / NCI NIH HHS / CA / CA036401-21
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Other-IDs] NLM/ NIHMS104861; NLM/ PMC2706830
  •  go-up   go-down


89. Malla A, Norman R, Schmitz N, Manchanda R, Béchard-Evans L, Takhar J, Haricharan R: Predictors of rate and time to remission in first-episode psychosis: a two-year outcome study. Psychol Med; 2006 May;36(5):649-58
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Predictors of rate and time to remission in first-episode psychosis: a two-year outcome study.
  • BACKGROUND: The evidence regarding the independent influence of duration of untreated psychosis (DUP) on rate and time to remission is far from unequivocal.
  • The goal of the current study was to examine the role of predictors for rate and time to remission in first-episode psychosis (FEP).
  • METHOD: The differential effect of age, gender, age of onset, duration of untreated psychosis (DUP), duration of untreated illness (DUI), pre-morbid adjustment, co-morbid diagnosis of substance abuse and adherence to medication on the rate of and time to remission were estimated using a logistic and Poisson regression, and survival analysis respectively, in FEP patients.
  • RESULTS: In a sample of 107 FEP patients 82.2% achieved remission over a period of 2 years after a mean of 10.3 weeks (range 1-72).
  • Regression analysis, based on complete data on all variables of interest (n=80), showed status of remission to be positively influenced by better pre-morbid adjustment (RR 0.57, 95% CI 0.34-0.95, p<0.05), later age of onset (RR 1.09, 95% CI 1.05-1.13, p<0.0001), higher level of adherence to medication (RR 1.96, 95% CI 1.38-2.76, p<0.001) and shorter DUI (RR 0.99, 95% CI 0.997-0.999, p<0.005).
  • Time to remission was influenced by age of onset (HR 1.04, 95% CI 1.00-1.08, p<0.04) and adherence to medication (HR 1.58, 95% CI 1.11-2.23, p<0.01).
  • [MeSH-minor] Adolescent. Adult. Age of Onset. Antipsychotic Agents / therapeutic use. Diagnosis, Dual (Psychiatry). Female. Humans. Male. Middle Aged. Ontario. Patient Compliance. Proportional Hazards Models. Regression Analysis. Remission Induction. Substance-Related Disorders / psychology. Survival Analysis. Time Factors. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Psychotic Disorders.
  • MedlinePlus Health Information. consumer health - Schizophrenia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16515734.001).
  • [ISSN] 0033-2917
  • [Journal-full-title] Psychological medicine
  • [ISO-abbreviation] Psychol Med
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antipsychotic Agents
  •  go-up   go-down


90. Del Felice A, Beghi E, Boero G, La Neve A, Bogliun G, De Palo A, Specchio LM: Early versus late remission in a cohort of patients with newly diagnosed epilepsy. Epilepsia; 2010 Jan;51(1):37-42
MedlinePlus Health Information. consumer health - Epilepsy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Early versus late remission in a cohort of patients with newly diagnosed epilepsy.
  • PURPOSE: To count patients with newly diagnosed epilepsy entering early and late remission and to identify prognostic predictors of late remission.
  • Early remission was defined by 2-year seizure control immediately after treatment start.
  • Late remission was defined by 2-year seizure control achieved at least 24 months after treatment start.
  • The cumulative time-dependent probability of 2-year remission was 56.3% at 2 years after treatment start, and 62.6, 69.4, and 79.5% at 3, 5, and 10 years.
  • One hundred fifteen patients (23.0%) achieved early remission and 38 patients (10.8%) achieved late remission.
  • The interaction between partial seizures and number of seizures prior to treatment was the only independent predictor of late remission.
  • DISCUSSION: The course of epilepsy and the chance of remission are together a complex and dynamic process, possibly explained by the diversity of the mechanisms underlying drug response and the use of an increasing number of drugs.
  • [MeSH-minor] Adolescent. Adult. Age of Onset. Aged. Aged, 80 and over. Child. Child, Preschool. Cohort Studies. Drug Resistance. Female. Follow-Up Studies. Humans. Italy / epidemiology. Kaplan-Meier Estimate. Male. Middle Aged. Probability. Prognosis. Remission Induction. Retrospective Studies. Risk Factors. Syndrome. Treatment Outcome

  • Genetic Alliance. consumer health - Epilepsy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19490039.001).
  • [ISSN] 1528-1167
  • [Journal-full-title] Epilepsia
  • [ISO-abbreviation] Epilepsia
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Multicenter Study
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anticonvulsants
  •  go-up   go-down


91. Rowe JM: Optimal management of adults with ALL. Br J Haematol; 2009 Feb;144(4):468-83
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The cure rate of acute lymphoblastic leukaemia (ALL) in adults remains unsatisfactory.
  • The remarkable progress in childhood ALL has not been replicated in adult ALL and approximately two thirds of patients younger than 60 years, and more than 90% of those over 60 years, are expected to succumb to their disease.
  • Over 80% of adults can achieve a complete remission; however, the majority of such patients relapse.
  • Prognostic factors have been more clearly defined, moving cytogenetics and molecular determinants forefront, much like acute myeloid leukaemia.
  • [MeSH-major] Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy
  • [MeSH-minor] Adolescent. Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Hematopoietic Stem Cell Transplantation / methods. Humans. Neoplasm, Residual. Prognosis. Remission Induction. Survival Analysis. Treatment Outcome. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19055668.001).
  • [ISSN] 1365-2141
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 102
  •  go-up   go-down


92. Nawata M, Saito K, Nakayamada S, Tanaka Y: Discontinuation of infliximab in rheumatoid arthritis patients in clinical remission. Mod Rheumatol; 2008;18(5):460-4
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Discontinuation of infliximab in rheumatoid arthritis patients in clinical remission.
  • Here, we document that infliximab could be discontinued after clinical remission in RA patients.
  • Among 172 patients with RA who reached clinical remission following infliximab (3 mg/kg) and methotrexate (MTX, >6 mg/w), nine patients with sustained remission discontinued it.
  • We considered patients for discontinuation of infliximab treatment after remission (DAS28-ESR<2.6) had been sustained for more than 24 weeks.
  • These nine patients all met the remission standard-that DAS28-ESR<2.6 for >or=24 weeks) -and so their treatment with concomitant drugs was discontinued.
  • After the discontinuation of infliximab, the mean period of sustained remission was 14.2 months and the longest period was 29 months.
  • Strategic reductions and/or discontinuations of concomitant treatment were performed in RA patients who attained clinical remission (DAS28<2.6) through treatment with infliximab and MTX.
  • Nine patients successfully discontinued infliximab after maintaining clinical remission for more than 24 weeks.
  • After infliximab was discontinued, clinical remission and suppression of joint destruction were maintained with MTX alone, especially in early RA patients.

  • Genetic Alliance. consumer health - Arthritis.
  • Genetic Alliance. consumer health - Rheumatoid arthritis.
  • Hazardous Substances Data Bank. Infliximab .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18535759.001).
  • [ISSN] 1439-7595
  • [Journal-full-title] Modern rheumatology
  • [ISO-abbreviation] Mod Rheumatol
  • [Language] ENG
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antirheumatic Agents; B72HH48FLU / Infliximab
  •  go-up   go-down


93. Shimokawa T, Kojima Y: [Gemtuzumab ozogamicin successfully induced molecular remission in relapsed therapy-related acute promyelocytic leukemia]. Rinsho Ketsueki; 2008 Apr;49(4):270-2
Hazardous Substances Data Bank. ETOPOSIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Gemtuzumab ozogamicin successfully induced molecular remission in relapsed therapy-related acute promyelocytic leukemia].
  • A 37-year-old woman was diagnosed with therapy-related acute promyelocytic leukemia (t-APL) in May 2006 after chemotherapy that included etoposide for ovarian cancer in November 2003.
  • After treatment with all-trans retinoic acid in combination with chemotherapy, complete remission was attained.
  • Molecular remission was attained without serious complication.
  • GO is considered a promising agent to achieve molecular remission in patients with relapsed t-APL.
  • [MeSH-major] Aminoglycosides / therapeutic use. Antibodies, Monoclonal / therapeutic use. Antineoplastic Agents / therapeutic use. Antineoplastic Agents, Phytogenic / adverse effects. Etoposide / adverse effects. Leukemia, Promyelocytic, Acute / chemically induced. Leukemia, Promyelocytic, Acute / drug therapy
  • [MeSH-minor] Adult. Antibodies, Monoclonal, Humanized. Female. Humans. Remission Induction

  • Genetic Alliance. consumer health - Acute Promyelocytic Leukemia.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18516871.001).
  • [ISSN] 0485-1439
  • [Journal-full-title] [Rinshō ketsueki] The Japanese journal of clinical hematology
  • [ISO-abbreviation] Rinsho Ketsueki
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Aminoglycosides; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antineoplastic Agents; 0 / Antineoplastic Agents, Phytogenic; 0 / gemtuzumab; 6PLQ3CP4P3 / Etoposide
  •  go-up   go-down


94. Miwa K, Fujita M: Cardiac function fluctuates during exacerbation and remission in young adults with chronic fatigue syndrome and "small heart". J Cardiol; 2009 Aug;54(1):29-35
MedlinePlus Health Information. consumer health - Chronic Fatigue Syndrome.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cardiac function fluctuates during exacerbation and remission in young adults with chronic fatigue syndrome and "small heart".
  • During a long follow-up period of 10 CFS patients with "small heart", all echocardiographic parameters mentioned above improved and cardiothoracic ratios increased significantly during the remission phase as compared with exacerbation phase.
  • [MeSH-minor] Adult. Echocardiography, Three-Dimensional. Female. Heart Ventricles / anatomy & histology. Humans. Male. Radiography, Thoracic

  • Genetic Alliance. consumer health - Young syndrome.
  • Genetic Alliance. consumer health - Chronic fatigue syndrome.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19632517.001).
  • [ISSN] 1876-4738
  • [Journal-full-title] Journal of cardiology
  • [ISO-abbreviation] J Cardiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


95. Cooper SA, Smiley E, Allan LM, Jackson A, Finlayson J, Mantry D, Morrison J: Adults with intellectual disabilities: prevalence, incidence and remission of self-injurious behaviour, and related factors. J Intellect Disabil Res; 2009 Mar;53(3):200-16
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adults with intellectual disabilities: prevalence, incidence and remission of self-injurious behaviour, and related factors.
  • There has been little study of remission rate, and incidence has not previously been reported.
  • This study investigates the point prevalence, incidence and remission rates of SIB among the adult population with intellectual disabilities (ID), and explores which factors are independently associated with SIB.
  • RESULTS: The point prevalence of SIB (as defined by DC-LD) was 4.9%, the two-year incidence was 0.6%, and two-year remission rate was 38.2%.
  • CONCLUSIONS: SIB is not as enduring and persistent as previously thought; a significant proportion gains remission in this time period.
  • The extent to which SIB may be a relapsing-remitting (episodic) condition requires further investigation, so does further hypothesis-based investigation of factors that might be predictive of incidence of, and remission from, SIB.
  • [MeSH-minor] Activities of Daily Living / classification. Adolescent. Adult. Cohort Studies. Communication. Comorbidity. Cross-Sectional Studies. Follow-Up Studies. Humans. Incidence. Middle Aged. Prospective Studies. Secondary Prevention. Young Adult

  • MedlinePlus Health Information. consumer health - Self-harm.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18444987.001).
  • [ISSN] 1365-2788
  • [Journal-full-title] Journal of intellectual disability research : JIDR
  • [ISO-abbreviation] J Intellect Disabil Res
  • [Language] eng
  • [Grant] United Kingdom / Department of Health / / CZH/4/96; United Kingdom / Chief Scientist Office / /
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


96. Ram R, Gafter-Gvili A, Vidal L, Paul M, Ben-Bassat I, Shpilberg O, Raanani P: Management of adult patients with acute lymphoblastic leukemia in first complete remission: systematic review and meta-analysis. Cancer; 2010 Jul 15;116(14):3447-57
PubMed Health. DARE review .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Management of adult patients with acute lymphoblastic leukemia in first complete remission: systematic review and meta-analysis.
  • BACKGROUND: The optimal postremission therapy in adults with acute lymphoblastic leukemia (ALL) is still a matter of debate.
  • The objective of this study was to compare the various potential therapeutic options for patients who achieved first complete remission.
  • CONCLUSIONS: Overall, alloSCT was superior to ASCT or chemotherapy for patients with ALL in first complete remission.
  • [MeSH-major] Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Humans. Randomized Controlled Trials as Topic. Recurrence. Remission Induction

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2010 American Cancer Society.
  • (PMID = 20564092.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Meta-Analysis; Review
  • [Publication-country] United States
  • [Number-of-references] 33
  •  go-up   go-down


97. Reuber M, Mitchell AJ, Howlett S, Elger CE: Measuring outcome in psychogenic nonepileptic seizures: how relevant is seizure remission? Epilepsia; 2005 Nov;46(11):1788-95
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Measuring outcome in psychogenic nonepileptic seizures: how relevant is seizure remission?
  • PURPOSE: To examine whether seizure remission is a comprehensive marker of outcome in psychogenic nonepileptic seizures (PNESs).
  • RESULTS: Of the patients, 71.4% continued to have seizures, and 28.6% had achieved seizure remission; 60.0% of patients with continuing seizures and 42.7% of patients in remission were "unproductive" (difference, NS).
  • CONCLUSIONS: Seizure remission is not a comprehensive measure of good medical or psychosocial outcome in PNESs.
  • [MeSH-minor] Adult. Female. Follow-Up Studies. Health Status. Humans. Male. Mental Disorders / diagnosis. Mental Disorders / psychology. Personality Inventory. Research Design. Severity of Illness Index. Surveys and Questionnaires. Treatment Outcome


98. Urquizu-Padilla M, Balada E, Cortés F, Pérez EH, Vilardell-Tarrés M, Ordi-Ros J: Serum levels of soluble CD40 ligand at flare and at remission in patients with systemic lupus erythematosus. J Rheumatol; 2009 May;36(5):953-60
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Serum levels of soluble CD40 ligand at flare and at remission in patients with systemic lupus erythematosus.
  • METHODS: Two serum samples were taken from 53 patients with SLE: at flare and at remission.
  • RESULTS: Patients with SLE had significantly lower median levels of sCD40L during flare than during remission [3365 (6157) vs 7125 (4122) pg/ml; p < 0.001].
  • The multivariate analysis to explain those patients with lower values of sCD40L during flare than during remission included 3 variables: 2 related to flare (prednisone dose received <or= 15 mg/day and platelet counts > 192,000 x 10(6)/l) and one related to lower changes in SLE Disease Activity Index (SLEDAI) score.
  • All patients with low SLEDAI scores at flare had statistically significant lower sCD40L levels during flare than during remission.
  • When flare SLEDAI scores were higher than the 50th percentile, patients of Group 123 showed the same behavior and even more diminished levels of sCD40L during flare than patients of Group 123 with low SLEDAI scores (p = 0.023); and patients of Group 4 showed no differences in the values of sCD40L between flare and remission (p = 0.241).
  • [MeSH-minor] Adolescent. Adult. Child. Disability Evaluation. Female. Health Status. Humans. Male. Middle Aged. Prospective Studies. Recurrence. Remission Induction. Severity of Illness Index. Young Adult

  • Genetic Alliance. consumer health - Lupus.
  • Genetic Alliance. consumer health - Systemic lupus erythematosus.
  • MedlinePlus Health Information. consumer health - Lupus.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19332622.001).
  • [ISSN] 0315-162X
  • [Journal-full-title] The Journal of rheumatology
  • [ISO-abbreviation] J. Rheumatol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Canada
  • [Chemical-registry-number] 147205-72-9 / CD40 Ligand
  •  go-up   go-down


99. Nibourel O, Kosmider O, Cheok M, Boissel N, Renneville A, Philippe N, Dombret H, Dreyfus F, Quesnel B, Geffroy S, Quentin S, Roche-Lestienne C, Cayuela JM, Roumier C, Fenaux P, Vainchenker W, Bernard OA, Soulier J, Fontenay M, Preudhomme C: Incidence and prognostic value of TET2 alterations in de novo acute myeloid leukemia achieving complete remission. Blood; 2010 Aug 19;116(7):1132-5
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Incidence and prognostic value of TET2 alterations in de novo acute myeloid leukemia achieving complete remission.
  • We analyzed the incidence and prognostic value of TET2 point mutations and other genomic alterations by direct sequencing and single nucleotide polymorphism microarray analysis in 111 de novo acute myeloid leukemia, who had all achieved complete remission (CR).
  • [MeSH-major] DNA-Binding Proteins / genetics. Leukemia, Myeloid, Acute / genetics. Mutation / genetics. Proto-Oncogene Proteins / genetics. Translocation, Genetic / genetics
  • [MeSH-minor] Adolescent. Adult. Aged. Biomarkers, Tumor / genetics. Biomarkers, Tumor / metabolism. Female. Gene Expression Profiling. Humans. Incidence. Karyotyping. Male. Middle Aged. Oligonucleotide Array Sequence Analysis. Polymorphism, Single Nucleotide / genetics. Prognosis. Remission Induction. Survival Rate. Young Adult

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20489055.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA-Binding Proteins; 0 / Proto-Oncogene Proteins; 0 / TET2 protein, human
  •  go-up   go-down


100. Messerer D, Engel J, Hasford J, Schaich M, Ehninger G, Sauerland C, Büchner T, Schumacher A, Krahl R, Niederwieser D, Krauter J, Ganser A, Creutzig U, Döhner H, Schlenk RF, German AML Intergroup: Impact of different post-remission strategies on quality of life in patients with acute myeloid leukemia. Haematologica; 2008 Jun;93(6):826-33
MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Impact of different post-remission strategies on quality of life in patients with acute myeloid leukemia.
  • BACKGROUND: The impact on quality of life of allogeneic stem cell transplantation or conventional chemotherapy in patients with acute myeloid leukemia remains unclear, mainly because of a lack of studies with long-term follow-up.
  • One hundred and seventy patients were treated with stem cell transplantation (121 allogenic, 49 autologous) in first complete remission; the other 249 patients were treated with conventional chemotherapy.
  • [MeSH-major] Leukemia, Myeloid, Acute / pathology. Leukemia, Myeloid, Acute / therapy. Remission Induction
  • [MeSH-minor] Adolescent. Adult. Disease-Free Survival. Female. Follow-Up Studies. Health Status. Humans. Male. Middle Aged. Quality of Life. Time Factors. Transplantation, Homologous. Treatment Outcome

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Haematologica. 2008 Jun;93(6):801-5 [18515876.001]
  • (PMID = 18469349.001).
  • [ISSN] 1592-8721
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  •  go-up   go-down






Advertisement